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ABSTRACT 
The study focuses on understanding the dynamic nature of interactions between molecules 
and macromolecules. Molecular modeling and simulation technologies are employed to 
understand how the chemical constitution of the protein, specific interactions and dynamics of its 
structure provide the basis of its mechanism of function. The structure-dynamics-func tion 
relationship is investigated from quantum to macromolecular-assembly level, with applications in 
the field of rationale drug discovery and in improving efficiency of renewable sources of energy. 
Results presented include investigating the role of dynamics in the following: 
1) In interactions between molecules: analyzing dynamic nature of a specific non-covalent 
interaction known as “anion-π [pi]” in RmlC protein.  
2) In interactions between molecules and macromolecules: defining the structural basis of 
testosterone activation of GPRC6A.  
3) In disrupting the function using specific substrate interactions: incorporating protein 
dynamics and flexibility in structure-based drug-discovery approach targeting the 
prothrombinase coagulation complex.  
4) In interactions between macromolecules: elucidating the protein-protein binding and 
dynamics of electron-transport proteins, Ferrodoxin and Cytochrome c6, with 
Cyanobacterial Photosystem I.  
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INTRODUCTION 
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Prologue 
Proteins are of critical importance for all living organisms. They perform an array of 
functions, including catalyzing metabolic reactions, maintaining structural integrity of the cell, 
transporting molecules from one location to another, to name a few. Proteins have a chemical 
nature defined by its amino acid sequence. This unique sequence of residues fold into unique three-
dimensional structures, which defines not only its size and shape but also its function (1). The 
three-dimensional structures can form complementary sites for binding other molecules, for 
example, active site in the case of reactions catalyzed by enzymes (2), and protein binding sites on 
protein surface in formation of oligomers (3). Hence, protein sequence and its structure can be 
compared to its fingerprint, where different structures represent different personalities and 
functions of the proteins.  
The function of a protein is also modulated by other molecules (4). Recognition and 
binding of a substrate to the protein involves specific interactions between protein residues and the 
substrate molecule. Covalent and non-covalent interactions play a critical role in maintaining the 
structural integrity of the protein itself (5,6). These interactions can be described both at the 
quantum scale with high accuracy, and by using semi-empirical and classical methods, that allow 
certain approximations. Hence, in order to understand the behavior of protein, it is important to 
understand and quantify all possible interactions that control protein structural integrity and drive 
its function (7).  
Biophysical methods like crystallography and NMR provide a static picture of the proteins  
(8,9). But, it is important to recognize that proteins are ‘alive’ molecules (10). They are flexible at 
room temperatures and can undergo changes in different interactions, leading to changes in its 
three-dimensional structure and function. This flexibility and stochastic fluctuations lead to 
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different ‘active’ and ‘non-active’ states of the protein, directing reactions preferentially along 
functionally important pathways (11). Thus, in order to exploit this quality of biological molecules, 
for example in medicine and renewable power generation, computational methods that simulate 
molecular structure and interactions can be employed in exploring the structures (and interactions) 
that are unresolved through experiments (12). 
 
Scope of Study 
Protein dynamics are central to understanding the structure-function correlation in 
biological systems (13). The study presented here characterizes the dynamic nature of interactions 
in proteins, protein: ligand and protein: protein systems, and in understanding the structural and 
dynamical properties of macromolecular systems that furnish their biological function using 
computational methods (14). In particular, this research describes a new non-covalent interaction 
in proteins at the quantum and macromolecular level, the structural basis of substrate 
interactions/activation and function is explored in a membrane protein, structure-based drug 
discovery methods are extended to include the inherent flexibility of biological molecules in order 
to make better predictions in protein-ligand binding, and protein-protein interactions and dynamics 
are studied at the macromolecule-systems level. 
Understanding and quantifying different interactions in biological systems opens the 
avenue for designing new proteins/peptides and molecules with novel properties. Modeling 
interactions between protein and small molecules forms an important area of research in 
discovering new drugs for life-threatening diseases (15). Also, understanding the interactions 
between different macromolecules, especially those involved in plant/bacteria photosystem, can 
be used to modify and improve the efficiency of these systems for electricity production (16). 
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Molecular Interactions 
Atom and molecules constitute matter and form a complex network of weak and strong 
interactions conferring specific properties to the matter. The same is true for biological molecules. 
This interplay between strong and weak interactions in a macromolecule like protein results in a 
unique structure for that protein. The primary structure of a protein is determined by the bonded 
interactions between its amino acids. Secondary structure like alpha helix and beta strands are 
defined by patterns of non-bonded interactions, like hydrogen bonds, between the main-cha in 
atoms. Anion-π are an emerging non-bonded interactions that are present in biomolecules between 
negatively charged amino acid side chains and the positively charged ring edge of aromatic groups  
(17,18). These interactions have also been beneficially exploited in field structure-based drug-
discovery and in development of effective inhibitors (19). 
CHAPTER 1 introduces the theory of anion-π interactions and recent advances made in 
this field. The study aims at investigating the chemical, structural and thermodynamic 
characteristics of the anion-π interactions in RmlC protein (20), and characterizes the time- and 
temperature dependent dynamic stability of these interactions using molecular dynamics (MD) 
simulations, potential of mean force (PMF) and semi-empirical quantum energy calculations. 
 
Structure and function 
The structure of a protein is determined by its primary sequence of amino acids, which is 
encoded by the sequence of nucleotides in the gene (DNA). This unique structure of the protein 
and its active site allows the protein to interact with and bind different ligands, conferring it a 
unique function. So, in order to better understand the biological function of proteins, it is 
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imperative to correctly model the binding, interactions as well as the structural changes involved 
when a ligand binds to the protein.  
G protein–coupled receptors (GPCRs) are heptahelical membrane receptors, that sense  
molecules outside the cell, activating inside signal transduction pathways and, ultimately, cellular 
responses (21). Steroid hormone Testosterone (T) plays a key role in development of reproductive 
tissues, muscles and bones (22), and has been shown to lead to the downstream signaling in a 
newly characterized Family C GPCR, GPRC6A (23). CHAPTER 2 deals with providing the 
structural evidence for the T binding to GPRC6A, using homology modeling and molecular 
docking, to gain additional insights into this role of T in the activation of GPRC6A. 
 
‘Dynamics’ bridges the gap 
Proteins are not static entities. At room temperature, they populate an ensembles of 
conformations. Transitions between these states occur on a variety of  time scales (ns to s), linking 
these ensemble of structures to functionally relevant phenomena such as allosteric signaling and 
enzyme catalysis (24,25). As proteins have this dynamic nature, changes in its structure also 
complement the interplay between different interactions that maintain both its structural integr ity 
and function. 
The prothrombinase (PTase) enzymatic complex, consisting of the enzyme factor Xa 
(FXa), and a protein cofactor, factor Va (FVa), catalyzes the cleavage of prothrombin (PT) leading 
to the formation of thrombin and clot-formation (26,27).  The goal in CHAPTER 3 is to target 
FXa within the PTase complex, but instead of seeking another active-site directed inhibitor that 
have the serious liability of excessive bleeding (28), MD simulations and ensemble-based high-
throughput virtual screening methods are used to identify compounds that bind to FXa and alter 
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the interaction between FXa and its cofactor FVa. These compounds have the potential to down-
modulate the PTase activity in an allosteric and non-competitive manner.  
 
Macromolecular assemblies 
The functions of macromolecules are inter-connected. All the pieces in the puzzle need to 
come together to make the system work. Some small molecules can interact and bind to a protein, 
leading to its downstream signaling, activating/deactivating several other members in the same 
pathway (24). The final function or product formation is the product of this long assembly line. 
Treating individual elements of the same pathway or system separately only provides an isolated 
view of the whole process. As the biological system are dynamic and complex, their behavior can 
be hard to predict from the properties of individual subunits. So, in order to better understand the 
whole process, the complete system needs to be modeled.  
Photosystem is an interesting biological system that converts light energy into chemical 
energy through a series of redox reactions between two large, multi-subunit proteins Photosystem 
II (PSII) and Photosystem I (PSI) (29), and electron-transport proteins like Ferredoxin (Fd) and 
Cytochrome c6 (Cytc6) (30,31). CHAPTER 4 aims at developing new structural models between 
the stromal and luminal domains of PSI and Fd and Cytc6, respectively, using rigid-body 
molecular docking. MD simulations are being utilized to examine the atomic-level intermolecular 
interactions and dynamics at the protein-protein interface in these proteins to further understand 
and illustrate the small changes taking place in the transfer of electrons between the separate 
subunits. 
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ANION-Π NETWORKS IN PROTEINS ARE 
HIGHLY DYNAMIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
Research described in this chapter is reproduced from a manuscript prepared by Karan Kapoor, 
Amit Upadhyay, Robert Hinde, Elizabeth Howell and Jerome Baudry. 
 
My contribution in the paper includes (1) Compiling and interpretation of the literature (2) 
Designing and carrying out all computation research (except solvent analysis) (3) Understanding 
the literature and interpretation of the results (4) Preparation of tables and figures (5) Writing and 
editing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
Abstract 
The dynamics of anion- , (or anion-quadrupole) interactions formed between negatively charged 
(Asp/Glu) and aromatic (Phe/Trp/Tyr) side chains is computationally characterized in RmlC 
(PDB: 1EP0), a homodimeric epimerase. Empirical force field-based molecular dynamics 
simulations shows anion-π pairs and triplets (anion-anion-anion-) being formed in 
conformations sampled by the protein, extending the anion-π interactions beyond those observed 
in the crystal structure. The combined energies from the anion-π interactions sampled during the 
protein trajectory may provide a significant contribution to the overall stability of the protein, with 
an average of -1.6 kcal/mol per pair. These results suggest that near-planar anion-π pairs can exist 
– sometimes transiently - both at the active site and the dimer interface, which may play a role in 
maintaining the structural stability and function of the protein. 
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Introduction  
Non-covalent interactions play a constitutive role in maintaining the structural integrity of 
proteins, as well as in protein-protein and protein-ligand interactions. In addition to the well-known 
and well-described hydrogen bonds, van der Waals interactions and hydrophobic interactions, 
other non-covalent bond interactions have been suggested to contribute to the stabilization of 
protein structures and of protein-ligand complexes Our current analysis and understanding of 
protein structure, protein-protein and protein-ligand interactions is in large part based on our 
understanding of non-bonded interactions between atoms, functional groups or molecular 
domains. Among non-bonded interactions, hydrogen bonds, van der Waals interactions, 
hydrophobic interactions, and ion pairs are well described and well understood. However, other 
types of non-bonded interactions have been suggested to contribute to the stabilization of protein 
structures and of protein-ligand interactions (1-7). One of these is the anion-π interactions between 
an anion and the aromatic ring. These interactions have previously been studied with a focus on 
electron-deficient π rings, by incorporating strong electron-withdrawing substituents such as 
fluorobenzene derivatives, fluoro-s-triazine, and tetrafluoroethene, and negatively charged 
molecules and ions, as well as in the case of metallacycles (8-11). The positive charge on the 
aromatic ring edge arises from the quadrupole moment of the ring, leading to the anion-quadrupo le 
or anion-π interaction with the negatively charged anion. Wheeler et al. have recently provided an 
alternative explanation for the origin of anion-π interactions involving substituted benzenes and 
N-heterocycles and suggested that the positive electrostatic potentials and molecular quadrupole 
moments characteristic of π-acidic azines, which underlie the ability of these rings to bind anions 
above their centers, arise from the position of nuclear charges, not changes in the π-electron density 
distribution. (12,13). 
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Anion-π interactions have also been found to be present in biomolecules between 
negatively charged amino acid side chains and the positively charged ring edge of aromatic groups. 
Small molecule analogs (benzene/phenol/indole interacting with formate) have been used to 
characterize the pairwise interaction of aromatic amino acids (phenylalanine, tyrosine, tryptophan) 
with anionic amino acids (aspartic and glutamic acids) at the MP2 level of quantum mechanica l 
(QM) theory (14). The study shows that the overall stabilization associated with an anion-π 
interaction to be potentially substantial, as large -9.5 kcal/mol for a benzene-formate (BF) planar 
dimer at van der Waals contact distance where the interaction is expected to be at a maximum.  
Studies by Kallenbach et al. using short α-helical peptides with glutamate/ phenylalanine 
pairs positioned at i and i+4 spacing indicate that this pairwise interaction provides ~0.5 kcal/mol 
additional stability to the helix (15-17).  Breberina et al. find a significant percentage of anion-π 
interacting residues located as stabilization centers in Sm/LSm proteins, with energies in the range 
-2 to -9 kcal mol-1 calculated by CHARMM22 (18). In the specific context of intermolecular 
binding interactions, Schwans et al. find two active site phenylalanines (F54, F116) help hold the 
general base (D38) in position for catalysis in ketosteroid isomerase (19). They also identified 46 
enzymes that appear to use an aromatic group to position Asp or Glu so that it can act as a general 
base in the mechanism, suggesting an important functional role in biology of anion-π interactions. 
These interactions have also been beneficially exploited in structure-based drug-discovery, where 
Sacchettini et al. developed effective inhibitors targeting malate synthase in Mycobacterium 
tuberculosis, where anion–π interactions play an important role (20). 
The energetics and structural properties of anion-π interactions present in the Protein Data 
Bank (PDB) have been investigated for Phe-Asp and Phe-Glu pairs (21). An average of ~3.4 anion-
π pairs per protein structure in the PDB were identified, and Kitaura-Morokuma (KM) QM analysis 
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indicates that 81% of these pairs exhibit stabilizing energies as low as -8.7 kcal/mol for pairs 
present at near-planar angles. Nearly planar aromatic- anionic amino acid pairs were also found to 
occur more often than expected from a random angular distribution, while axial aromatic-anionic 
pairs occur less often than expected from a random distribution, suggesting a contribution of 
anion–π interactions to protein stability.  
A number of proteins that exhibit clusters of such interactions have been identified (21). 
Some of these clusters involve relatively long and linear chains of anion-π interactions, or several 
anions clustering around a single resonant side chain. Pairs occur in α helices as well as in β strands 
and sometimes form “anion-π networks” involving several amino acids. In crystal structure of one 
of these proteins, RmlC, a homodimeric deoxythymidine diphosphate epimerase (dTDP-4-keto-6-
deoxy-d-hexulose 3,5-epimerase; PDB code 1EP0) a network of five anion-π pairs (in the 
monomer) was identified involving seven neighboring residues.  
There is hence a growing body of results, theoretical and experimental, that points to the 
structure, thermodynamic and functional importance of anion-π interactions in biomolecules. The 
previous work has essentially focused on static structures however, and essentially focused on the 
enthalpy of anion-π interactions.  The present work aims at investigating the dynamics 
characteristics of the anion-π network in RmlC using Molecular dynamics (MD) simulations. In 
particular we investigate whether the Phe-Asp or Phe-Glu anion-π interactions identified in the 
crystal structure remain stable on the free energy surface sampled by the protein, or whether these 
interactions are 'drowned out' by solvent interactions and/or otherwise larger scale protein 
dynamics.  Inversely, we investigate if anion-π interactions that would not been observed in the 
crystal structure appear in the dynamics, because, for instance, crystal packing forces could (22) 
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‘drown out’ otherwise relatively weak anion-π interactions initially present at non-ideal 
geometries.  
 
Materials and methods 
Anion-π cluster in RmlC 
Deoxythymidine diphosphate (dTDP)-4-keto-6-deoxy-d-hexulose 3,5-epimerase (RmlC; 
PDB ID- 1EP0), a homodimer with each monomer consisting of 183 residues, is involved in the 
biosynthesis of dTDP-l-rhamnose which is an essential component of the bacterial cell wall (23). 
The dimer interface is formed by an extensive set of hydrophobic and electrostatic contacts. 
Charged residues (Asp-24, Arg-26, Glu-35, Asp-50, Glu-52, Arg-61, Arg-76, Lys-134) and 
aromatic residues (Tyr-28, Phe-33, Phe47) are present at this interface. The substrate binding site 
is also lined with a number of charged residues (Asp-24, Arg-26, Glu-31, Glu-52, Arg-61, His-64, 
Lys-73, Asp-84, His- 120, Asp-144, Lys-171, Asp-172) and aromatic residues (Phe-29, Phe-122, 
Tyr-133, Tyr- 139, Trp-175).  
The crystal structure was analyzed with the STAAR (STatistical Analysis of Aromatic 
Rings) program (24). STAAR locates phenylalanine rings and determines their centers of mass 
(CM). For each aromatic ring, STAAR then calculates the distance r between the ring’s center of 
mass and the center of charge (CC) for the Glu or Asp carboxylate group, as well as the angle θ 
between the plane of the ring and the vector connecting the ring center of mass with this center of 
charge. The cutoff criteria of Gallivan and Dougherty (25) was adopted i.e., those pairs possessing 
a distance r of <= 7 Å were chosen for analysis to eliminate cases in which a water molecule could 
fit between the two residues and diminish the interaction energy. The Phe and Glu or Asp anion-π 
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pairs identified, both intramolecular and intermolecular, were then parsed from the STAAR output 
for their respective distance and angles using perl scripts. 
 
MD Simulations  
The dynamics of the RmlC dimer was characterized in molecular dynamics (MD) 
simulations. The asymmetric unit representing the dimer was generated using the biologica l 
assembly of the RmlC X-ray crystal structure (PDB code: 1EP0) (23). This PDB entry has a 1.50 
Å resolution, and no gaps in the structure. The structure was protonated according to estimated 
PkAs using the Protonate-3D facility in MOE-2010 (26), with an ion concentration of 0.1 mol/L 
in the Generalized Born (GB) electrostatics model. Crystallographic water molecules were 
retained and a periodic solvation cube of water molecules was created using the Solvate facility in 
MOE-2010. Twenty-six positive sodium ions were added to neutralize the system and the final 
system consisted of 47892 atoms, with 14,002 water molecules.  
In previous studies the correlation between the CHARMM-22 force-field (27) and ab init io 
interaction energies has shown that the ab initio anion-π interaction energies can be reproduced 
correctly by the CHARMM empirical force field for basic functional groups, albeit with a 
magnitude that underestimates the ab initio results by up to ∼50% (14,21). The system was energy-
minimized to a gradient of 10-5 RMS kcal/mol/Å2 using  a 8Å -10Å nonbonded cutoff distance. 
NAMD2 input files were generated using the Dynamics facility in MOE-2010. A time-step of 2 
fs/step was used for all calculations and water molecules were held rigid. A constant temperature 
of 300K was maintained throughout the simulation using Langevin dynamics. Particle Mesh 
Eswald (PME) was used for calculation of the electrostatic interactions with the periodic boundary 
conditions.  
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MD simulation of the complete system using NVT ensemble was performed on the 
University of Tennessee High Performance Computing architecture (Newton), using the NAMD2 
simulation engine (28). A 100 ps initial equilibration was ran followed by a 150 ns production run 
with structures saved at every 250 timesteps (0.5ps), giving a total of 300,200 trajectory frames 
including 200 frames (100ps) for equilibrium of the system. The resulting trajectories were 
analyzed for convergence of temperature and RMSD using perl scripts to parse data, Prody v1.2 
(29) and Gnuplot v4.6.  
 
Anion-π pair analysis in MD simulation 
The trajectory files in DCD format from the MD production run were converted to PDB 
format using Prody v1.2, generating a total of 300,000 structures, i.e., one for each trajectory 
frame. Perl scripts were used to modify these files to make them compatible with STAAR. The 
names of the amino acid residues, residue numbers, atom names and chain-ID were parsed from 
the starting PSF file using perl scripts and added to the generated PDB files to maintain consistency 
in residue naming and numbering. These snapshots were parsed with the STAAR program for Phe-
Glu or Asp pairs with a threshold distance of 11 Å. The anion-π pairs present in the crystal structure 
were parsed from the STAAR output for their respective distance and angles using perl scripts.  
Distance and angle plots were generated using Gnuplot-4.6.  
The STAAR output was again parsed for Phe-Glu or Asp pairs not seen in the crystal 
structure but that may form in the monomer during the course of the MD simulation, with a 
threshold distance of 6 Å (6 Å or below at any point during MD) between the pairs using perl 
scripts. The output was also parsed for anion-π pairs present between the two monomers 
(intermolecular) with the same threshold distance.  
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Solvent Analysis 
To quantify the amount of water molecules that can possibly interact and shield the 
interactions between the partners of the anion-π pairs identified by STAAR, the center of mass for 
Phe and the center of charge for Asp/Glu were obtained by parsing the STAAR output files. The 
number of water molecules for a given anion-π pair was calculated according to two different 
criteria: (i) number of water molecules within 4 Å of the center of mass of Phe and 4 Å of the 
center of charge of the anion, and (ii) water molecules in the region located between the Phe residue 
and the anion for a given anion-π pair. The latter was calculated by first determining the 
coordinates of the midpoint between the center of mass of Phe residue and the center of charge of 
the anion. The distance threshold was chosen as half of the distance between the center of mass of 
Phe residue and the center of charge of the anion.  
 
Semi-empirical quantum energy calculations 
The STAAR program was used to perform the quantum energy calculation as described in 
earlier work (24). Briefly, the approach is to reduce the Phe and Glu or Asp pairs identified to 
benzene-formate (BF) pairs, followed by addition of hydrogens to the BF pairs using ProDrg2 
(30). As the pKa values for Asp and Glu are low (i.e., 3.5 - 4.5) (31), Asp and Glu are sassumed 
to be ionized. The resulting file are converted from PDB coordinates to an xyz format using Babel 
v2.3.3 (32) and the appropriate input files for PC GAMESS (June 1999 version) (33) generated. 
PC GAMESS running a Kitaura-Morokuma (KM) energy decomposition analysis (34,35) was 
used for interaction energy calculation between the anion-π pairs. GAMESS energy calculat ions 
were performed on these pairs for every 200th point i.e. at a time interval of 100ps. Hence, 
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interaction energies were calculated for a total of 1500 snapshots for each pair in the MD trajectory. 
Perl scripts, Excel spreadsheets and Macros were used to sort through the data.  
 
Potential of Mean force (PMF) 
 The PMF describes the free energy changes of a system as a function of reaction 
coordinates of the system (36). Here, the distances ‘R’ and angles between the anion-π pairs were 
used to generate angle-distance frequency distribution over the entire trajectory. For normalizing 
this frequency distribution, 1 million points were randomly distributed on a unit sphere using 
python scripts, and the distribution of points at different polar angles (0 to 180°) was calculated. 
Figure S1 and S2 show the resulting Gaussian distribution of these points. The area of sphere (and 
solid angle) is proportional to R2. Accordingly, the distribution of points with same probability 
density function and at different distances (different sphere radii) was also calculated. Figure S3 
shows the resulting exponential distribution of these points. The random distribution of points 
based on angles and distances was used to normalize the angle-distance frequency distribution 
over the entire trajectory.  
The normalized frequency distribution was used to generate the corresponding free energy 
maps for the anion-π pairs investigated here. For Potential of mean force (PMF) calculations the 
following equation was used: 
ΔG = -kT*ln(distribution ratio) 
With k = 0.5961 kcal/mol at T=300K. 
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Results 
Anion-π cluster in the RmlC crystal structure 
Anion-π interactions in RmlC crystal structure were found to consist of a total of ten anion-
π pairs, eight intramolecular and two intermolecular, comprising two clusters of four and five 
anion-π pairs at the dimer interface and in the monomer respectively, shown in Figure 1A, and 
their respective distance and angles are given in Table 1. The intramolecular clusters in the 
monomers each consist of interactions between seven residues (Figure 1B). The cluster shows the 
presence of several aromatic groups surrounding one anion, Phe122 and Phe112 around Asp84 
and Phe38 and Phe4 around Glu111 respectively, forming possible π-π-anion triplets, Anions, Glu-
31 and Glu-111, can also be seen to cluster around one aromatic group, Phe-4, forming an anion-
π-anion triplet. Out of the residues forming this cluster, two residues- Glu31 and Phe122, are 
present in the active site of the protein. 
The intermolecular cluster at the dimer interface consists of interactions between eight 
residues (Figure 1C). The cluster also contains possible π-π-anion (Phe33-Phe47-Asp50) and 
anion-π-anion (Glu35-Phe33-Asp50) triplets. Two symmetrical intermolecular pairs, Phe33-
Asp50 and Asp50-Phe33 (Phe and Asp residues present in separate monomers), are present in this 
cluster.   
 
MD Simulations and Anion-π pair analysis  
Figure S4 shows the RMSD plot for the protein backbone over the time course of the 
trajectory. Based on the RMSD plot, the RmlC homodimer is stable,  stabilizing after the first 2 ns 
of the production run around the value of 3.5 Å. The ten anion-π pairs present in the crystal 
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structure are found to sample different sidechain conformations in the MD snapshots, as shown in 
Figure S5.  
Distance vs time and angle vs time plots for the eight intramolecular pairs present in the 
crystal structure are shown in Figures S6A and S6B respectively, and the minimum, maximum 
and average distances and angles for each pair are given in Table 2. These pairs sample distance 
between 4 - 8 Å and angles 0 - 60°. The minimum average distances and angles are shown by 
Phe112- Asp84, whereas the maximum distances and angles are shown by Phe47- Asp50 and 
Phe118- Asp88 respectively. Noticeably, the pair Phe122- Asp84 samples planar configurat ions 
intermittently throughout the trajectory. Distance vs time and angle vs time plots for the two 
intermolecular pairs present in the crystal structure are shown in Figures S6C and S6D 
respectively, and the minimum, maximum and average distances and angles are given in Table 2. 
These two anion-π pairs, Phe33-Asp50 and Asp50-Phe33 (first and second residues present in 
separate monomers), sample distances between 4 - 6 A and angles between 0 - 40°.  
In addition to these pairs, a total of seven intra-molecular Phe-Glu or Asp pairs were seen 
appearing during the MD simulation and not in the starting crystal structure, showing distances < 
6 Å at some point in the trajectory (Figure 2A). Distance vs time and angle vs time plots are shown 
in Figures 2B and 2C respectively, and the minimum, maximum and average distances and angles 
sampled by each pair, along with the distances and angles seen in the crystal structure are given in 
Table 3. The pairs contain two anion-π-anion triplets, with one of these (Glu31-Phe29-
Asp24)present at the active site of the protein, and the other (Glu116-Phe113-Glu44) present in 
both monomers. These seven pairs were also found to sample different sidechain conformations, 
as shown in Figure S7. The pairs sample distance between 5 - 10 Å and angles 0 - 60°. The 
minimum average distances and angles are shown by Phe33-Glu111 and Phe113-Glu116, whereas 
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the maximum distances and angles are shown by Phe113-Glu44 and Phe4-Glu3, respectively. 
Phe4-Glu3 and Phe83-Asp157 transition between 'close' and 'distant' conformations with the 
corresponding transitions observed in the angles as well. Out of these, Phe4-Glu3 transitions 
between conformations that are closer in distance with the corresponding angles becoming more 
planar, whereas Phe83-Asp157 transitions between conformations that are closer in distance with 
the corresponding angles becoming more axial. These pairs may form anion-π interactions 
intermittently whenever the distance/angle falls below a certain threshold. Phe113-Glu44 also 
shows transition to the 'close' conformation at around 75 ns. 
 
Solvent Analysis 
The simulations showed that considerable number of water molecules may be present 
surrounding the anion-π pairs as well as between the pairs compared to the crystal structure. The 
number of water molecules surrounding each of the partners in the anion- π pairs is shown in 
Figure S8 and Table 4. In case of intramolecular pairs that were identified in the crystal structure, 
the maximum number of water molecules during the course of the simulation was lowest for 
Phe112-Asp84 and Phe122-Asp84 with three water molecules each (Figure S8A). There were no 
water molecules surrounding these pairs in the crystal structure even after explicit solvation. The 
largest number of water molecules was observed for Phe33-Glu35 followed by Phe4-Glu31 and 
Phe47-Asp50, all of which involve residues located near the surface of the protein. Considering 
the number of water molecules between the residues of the anion- π pairs, no water molecules were 
found to be present between Phe118-Asp88 (Figure 3A and Table 4), while the largest number of 
water molecules were observed for Phe33-Glu35, Phe47-Asp50 and Phe4-Glu31. Pairs comprising 
of partners near the surface, in general, showed more water molecules surrounding the pairs as 
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well as between the pairs (Table 4). In case of inter-molecular pairs, the number of water molecules 
surrounding the residues ranged from 1-9 at different points during the simulation (Figure S8B). 
The number of water molecules between the partners of the pairs ranged from 0-2 (Figure 3B).  
For anion pairs identified by MD simulations and not observed in the crystal structure, the 
number of water molecules was much higher. The surrounding water ranged from 0-17 (Figure 
S8C) while water molecules between the pairs ranged from 0-12 (Figure 3C). Phe4-Glu3 shows 
least number of water molecules corresponding to the times when the pairs transition to 
conformations that are closer in distance ('close' conformations). Phe33-Glu111 pair was 
associated with the least number of water molecules throughout the simulation amongst the non-
crystal structure pairs. The non-crystal structure pairs involved at least one residue which is close 
to the surface corresponding with the large number of water molecules associated with these pairs 
(Table 4). 
 
Semi-empirical quantum energy calculations 
The KM energy vs time plots for the ten anion-π pairs present in the crystal structure are 
shown in Figure 4A and 4B. The minimum, maximum and average interaction energies for these 
pairs during MD are given in Table 5, along with the interaction energies seen in the crystal 
structure. These pairs show energies ranging between +3 to -8 kcal/mol, with lower energies 
observed for pairs sampling shorter distances and near-planar angles, and vice-versa. Except Phe4- 
Glu111, all pairs sample lower energy conformations at some point during MD than that seen in 
crystal structure. The lowest interaction energy of -7.53 kcal/mol is shown by Phe38- Glu111, 
whereas Asp50-Phe33 shows the most prominent change (ΔE of -4.83 kcal/mol) between the 
minimum energy shown during MD and the crystal structure. Phe122-Asp84 intermittently shows 
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low energy configurations (~ -7 kcal/mol) corresponding to the times it samples planar angles. 
Phe47- Asp50 shows ~ 0 kcal/mol throughout the trajectory, as the distance and angle between 
this pair were stable at around 8 A and 45° respectively.  
The energy vs time plot for the seven anion-π pairs only seen during the simulation are 
shown in Figure 4C, and the minimum, maximum and average interaction energies for these pairs 
along with the interaction energies seen in the crystal structure are given in Table 6. These pairs 
too sample lower energy conformations during MD than that seen in crystal structure, with Phe33-
Glu111 showing both the lowest energy (-4.71 kcal/mol) and the most prominent change (ΔE of -
3.21 kcal/mol) between the minimum energy structure in MD and the crystal structure. Phe4-Glu3 
and Phe83-Asp157 show negative and positive energies intermittently at the times in the trajectory 
when the pairs sample planar and axial angles respectively. Phe113-Glu44 shows an interaction 
energy of -2.37 kcal/mol at 75 ns where it samples the 'close' configuration. 
 
Potential of Mean force  
The free energy maps of one intramolecular and one intermolecular anion-π pair present in 
the crystal structure, as well as one pair appearing during the MD simulation are shown in Figure 
5. The free energy maps for all other pairs are shown in Figure S9. 
Figure 5A shows an anion-π pair exhibiting average values of distances and angles close 
to the values seen in the crystal structure. These relatively small dynamics variations exhibit a 
narrow distance (~4.0 to ~6.3 Å) and angles (0 to ~44°) range sampled by this specific anion-π 
pair. The corresponding PMF (Figure 5B) correspondingly exhibit a narrow free energy basin of 
the energy landscape. 
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Figure 5C shows one of the symmetrical intermolecular anion-π pairs showing dynamic 
variations corresponding to a slightly wider range of distances (~3.8 to ~6.6 Å) and angles (0 to 
~60). The pair shows average values of distances and angles during the MD close to the values in 
the crystal structure but with larger fluctuations. The corresponding PMF (Figure 5D) indicates a 
relatively wider associated free energy basin. 
Figure 5E shows an anion-π pair only seen during the MD simulation showing dynamic 
variations with a wide range of distances (~4.8 to ~10.9 Å) and angles (10 to ~76°), sampling 
'close' and 'distant' states (relative to the conformation in the crystal structure) intermittent ly 
throughout the simulation. The pair samples distances and angles both above and below the values 
shown in the crystal structure (Table 3). The PMF (Figure 5F) indicates two possible free energy 
minimas. 
 
Discussion 
Proteins are not static structures, but undergo dynamical variations at room temperature 
and in solution that can lead to changes in the amount and strength of anion-π interactions. Some 
relatively weak anion-π interactions cease to be present, and some new interactions are formed 
over time. Out of the twelve negatively charged or aromatic amino acid residues present at the 
dimer interface and the active site of the protein, nine have been shown to possibly form anion- π 
interactions (Asp-24, Phe-29, Glu-31, Phe-33, Glu-35, Phe47, Asp-50, Asp-84, Phe-122). Among 
these, two symmetrical pairs, Phe33-Asp50, are present at the dimer interface, and an anion-π 
triplet, Glu31-Phe29-Asp24, is present at the active site of RmlC. Together these results suggest 
that anion-π interactions may contribute to both the structural stability and the function of the  
protein.  Possible anion-π pairs and triplets only observed in other conformations sampled by the 
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protein during the MD form an extensive network of anion-π interactions extending through most 
of the protein structure (Figure 6A and 6B).  
From the previous analysis of the PDB, edgewise geometries (small θ values between the 
pairs) are found to be more common than would be expected from a random distribution (21). At 
the same time, QM calculations of optimized BF (benzene-formate) pairs (14) show that the 
strongest interaction energies are also associated with edgewise interactions (-9.5 kcal/mol for 
planar BF dimer). This trend continues to be seen during the MD simulation of RmlC, with sixteen 
out of the seventeen pairs showing average angle values of less than 45°. As expected, fifteen out 
of these seventeen pairs show negative (i.e., stabilizing) average interaction energies as calculated 
by the KM energy decomposition analysis (Table 5 and 6), with the minimum energies shown by 
the pairs at near planar angles. The calculated interaction energies for the pairs during MD can be 
more stabilizing (by up to -4.8 kcal/mol for Asp50- Phe33) than the interaction energy calculated 
in the crystal structure, indicating that the pairs are able to sample lower energy conformations not 
seen in the crystal structure.  While some of these anion-π interactions are relatively weak, they 
are still significantly above kT (i.e., ~0.6 kcal/mol at 300 K) and can occur frequently. The 
combined ΔE from the seventeen pairs may provide a significant contribution to the overall 
stability of the protein, with an average of -1.6 kcal/mol per pair.  
The PMF calculated for all the pairs (Figure 5 and Figure S9) shows that some pairs are 
very stable throughout the molecular dynamics simulations, while some other pairs are only 
transiently formed, with both narrow and wide free energy basins of the energy landscape, 
respectively. This indicates the variable amount of stability provided by these interactions to the 
protein structure, with pairs with narrow free energy basins likely sampling conformations close 
to the native state for these pairs and hence more stable.  The wide fluctuations in the angles and 
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distances of some of the pairs (Figure 5E and S9) transitioning between 'close' and 'distant' states 
and corresponding to wide PMF variations, can partly be attributed to the lack of convergence over 
the simulation time scale (150 ns).  
The effects of the solvent molecules on the polarization of surrounding organic moieties 
are implicitly incorporated in the effective charges and other parameters of the pair-additive force 
fields (37). As an electrostatic component of the anion-π interaction exists, the burial of the pair 
would minimize potential disruption of the anion-π geometry by water (14,21). As can be expected, 
pairs comprising of partners near the surface exhibit more water molecules surrounding the pairs, 
and show relatively larger fluctuations in distances and angles (Table 3 and 4) than more buried 
pairs. On the other hand, well buried pairs like Phe112-Asp84 and Phe122-Asp84 are exposed to 
very few waters throughout the simulations, and show low fluctuations in distances and angles. 
These variations in angle and distance are not due only to solvent screening, but to otherwise more 
crowded environments. Nonetheless, some pairs form anion-π only intermittently ('close' and 
'distant' conformations), likely because one or both of the anion- π partners prefer at time to interact 
with the nearby water molecules than with each other, preventing the pairs from staying in the 
favorable 'close' conformations at planar angles for long periods of time.  
Previous comparisons of ab-initio and empirical force fields calculations of anion- π  
interactions indicate that the agreement between these two approaches is qualitatively correct, but 
that empirical force fields can underestimate the ab-initio calculated interaction energies for anion-
π interactions by about 50% (14,21), especially close to the low distance / low angle values of the 
anion-π pairs geometries. This means that the strength of interactions may be underestimated in 
the present MD simulations. The of observations made here, based on using an empirica l 
forcefield, will need to be further validated in future experiments looking at the stability of the 
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proteins by mutagenesis studies, and by using new polarizable force fields like Amoeba (38) and 
Drude (39) that explicitly include polarization in their parameterization and in calculation of the 
forces. This will characterize the interplay between the strength of anion-π interactions and the 
folding and stability of the protein structure.   
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Table 1.1. Anion-π pairs in crystal structure. The Phe and Glu or Asp anion-π pairs identified, 
both intramolecular and intermolecular, and their respective distance and angles in the crystal 
structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intra-/Inter-
molecular pairs 
Residue-1 Rsidue-2 Distance 
(A) 
Angle 
(deg) 
Intra Phe112 Asp84 4.59 0.62 
Intra Phe38 Glu111 5.49 0.74 
Intra Phe4 Glu31 5.03 0.10 
Intra Phe122 Asp84 5.11 23.98 
Intra Phe33 Glu35 6.09 4.98 
Intra Phe4 Glu111 6.17 12.33 
Intra Phe47 Asp50 6.88 36.01 
Intra Phe118 Asp88 4.31 73.86 
Inter Phe33 Asp50 5.02 33.28 
Inter Asp50 Phe33 5.02 33.28 
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Table 1.2. Distances and angles of anion-π pairs in crystal structure . The minimum, maximum 
and average distances and angles for the ten anion-π pairs during MD simulation. 
 
 
 
 
 
 
 
 
 
Anion-π pairs  Min 
Distance 
(A) 
Max 
Distance 
(A) 
Avg 
Distance 
(A) 
Min 
Angle 
(deg) 
Max 
Angle 
(deg) 
Avg 
Angle 
(deg) 
Phe112- Asp84 3.94 6.32 4.75 0.00 43.83 6.56 
Phe38- Glu111 3.90 6.76 4.89 0.00 44.74 12.92 
Phe4- Glu31 3.73 6.74 5.07 0.00 61.77 17.91 
Phe122- Asp84 3.91 6.39 4.89 0.01 68.62 35.76 
Phe33- Glu35 4.73 8.18 6.29 0.00 36.50 6.63 
Phe4- Glu111 5.44 9.71 7.41 0.01 85.34 27.23 
Phe47- Asp50 6.08 9.26 7.94 13.69 75.10 44.87 
Phe118- Asp88 3.02 5.73 4.44 17.99 89.95 69.88 
Phe33- Asp50 3.75 6.61 4.83 0.03 60.44 28.10 
Asp50- Phe33 3.85 6.87 4.88 0.00 55.30 20.40 
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Table 1.3. Distances and angles of anion-π pairs seen during MD simulation. The minimum, 
maximum and average distances and angles for the seven anion-π pairs only seen during MD 
simulation. The respective distances and angles values in the crystal structure are shown in 
brackets. 
 
 
 
 
 
 
 
 
 
 
 
Anion-π pairs 
(distance, angle 
in Xtal) 
Min 
Distance 
(A) 
Max 
Distance 
(A) 
Avg 
Distance 
(A) 
Min 
Angle 
(deg) 
Max 
Angle 
(deg) 
Avg 
Angle 
(deg) 
Phe33-Glu111 
(7.13, 13.60) 
5.12 8.43 6.45 0.00 44.68 10.99 
Phe29-Glu31  
(7.23, 12.95) 
4.85 9.51 7.41 0.00 68.39 21.58 
Phe4-Glu3      
(8.84, 54.98) 
4.75 10.86 8.94 0.06 75.79 38.05 
Phe83-Asp157 
(8.39, 26.80) 
5.89 10.94 9.09 1.91 73.89 32.22 
Phe29-Asp24  
(8.99, 34.49) 
5.83 10.01 7.74 0.76 58.07 28.59 
Phe113-Glu116 
(8.42, 10.11) 
5.70 10.99 8.70 0.00 40.84 10.17 
Phe113-Glu44 
(8.11, 41.71) 
5.31 10.99 9.40 0.02 58.17 24.38 
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Table 1.4. Solvent analysis of anion-π pairs. The minimum and maximum number of water 
molecules for the ten anion-π pairs (present in crystal structure) and seven anion-π pairs only seen 
during MD simulation. 
 
Anion-
π pairs  
Depth (A.u.) Surrounding Between 
Phe 
Depth 
Anion 
Depth 
Xtal 
Solvated 
Xtal 
Min Max Xtal 
Solvated 
Xtal 
Min Max 
Phe112-
Asp84 
9.85 
9.58 
0 0 0 3 0 0 0 1 
Phe38-
Glu111 
8.08 
9.86 
1 1 0 5 0 0 0 1 
Phe4-
Glu31 
5.5 
4.29 
1 4 1 12 0 0 0 4 
Phe122-
Asp84 
10.59 
9.58 
0 0 0 4 0 0 0 2 
Phe33-
Glu35 
4.59 
4.2 
2 4 1 14 1 1 0 5 
Phe4-
Glu111 
5.5 
9.86 
2 2 1 7 0 0 0 2 
Phe47-
Asp50 
6.41 
3.85 
2 1 1 8 0 1 0 5 
Phe118-
Asp88 
8.48 
8.02 
0 0 0 3 0 0 0 0 
Asp50-
Phe33 
4.59 
3.85 
2 1 1 8 0 0 0 2 
Phe33-
Asp50 
4.59 
3.85 
1 2 1 9 0 0 0 2 
Phe33-
Glu111 
4.59 
9.86 
1 1 1 6 1 1 0 3 
Phe29-
Glu31 
4.04 
4.29 
0 3 1 15 0 2 0 12 
Phe4-
Glu3 
5.5 
3.86 
1 4 0 18 1 1 0 17 
Phe83-
Asp157 
6.67 
3.95 
1 6 3 15 1 3 0 13 
Phe29-
Asp24 
4.04 
4.09 
2 1 2 16 2 6 1 14 
Phe113-
Glu116 
9.24 
4.66 
1 4 2 14 1 0 0 11 
Phe113-
Glu44 
9.24 
3.77 
0 6 0 16 1 3 0 15 
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Table 1.5. Interaction energies of anion-π pairs in crystal structure. The minimum, maximum 
and average interaction energies for ten anion-π pairs during MD, along with the interaction 
energies seen in the crystal structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anion-π pairs  Min 
Interaction 
energy 
(kcal/mol) 
Max 
Interaction 
energy 
(kcal/mol) 
Avg 
Interaction 
energy 
(kcal/mol) 
Xtal 
Interaction 
energy 
(kcal/mol) 
Phe112- Asp84 -7.37 +0.2 -5.09 -6.44 
Phe38- Glu111 -7.53 -0.99 -4.65 -4.83 
Phe4- Glu31 -6.86 +0.13 -3.18 -3.62 
Phe122- Asp84 -7.29 +1.3 -1.58 -2.87 
Phe33- Glu35 -4.62 -0.64 -1.98 -2.21 
Phe4- Glu111 -0.94 +0.24 -0.71 -2.09 
Phe47- Asp50 -0.97 +0.56 -0.21 -0.32 
Phe118- Asp88 -2.87 +2.98 +1.13 + 1.45 
Phe33- Asp50 -6.02 +0.61 -2.53 -2.48 
Asp50- Phe33 -7.31 +0.25 -3.59 -2.48 
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Table 1.6. Interaction energies of anion-π pairs seen during MD simulation. The minimum, 
maximum and average interaction energies for seven anion-π pairs only seen during MD 
simulation, along with their interaction energies in the crystal structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anion-π pairs  Min 
Interaction 
energy 
(kcal/mol) 
Max 
Interaction 
energy 
(kcal/mol) 
Avg 
Interaction 
energy 
(kcal/mol) 
Xtal 
Interaction 
energy 
(kcal/mol) 
Phe33-Glu111 -4.71 -0.7 -2.10 -1.50 
Phe29-Glu31 -2.74 +0.18 -0.89 -1.13 
Phe4-Glu3 -2.41 +0.37 -0.14 +0.20 
Phe83-Asp157 -0.5 +0.68 -0.15 -0.35 
Phe29-Asp24 -1.42 +0.22 -0.55 -0.31 
Phe113-Glu116 -1.9 -0.02 -0.65 -0.72 
Phe113-Glu44 -2.37 +0.09 -0.31 -0.05 
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Figure 1.1. Anion-π pairs in crystal structure. The two monomers are shown in grey and pink 
ribbon conformation. (A) Intrarmolecular cluster in two monomers shown in green, intermolecular 
cluster at dimer interface shown in orange, and a single anion-π pair shown in pink. Substrate 
dTDP bound in the active site shown in space-filling configuration. (B) Intramolecular and (C) 
Intermolecular cluster (residues in separate monomers colored grey and pink). 
 
A 
C B 
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Figure 1.2. Distances and angles of anion-π pairs seen during MD simulation. The two 
monomers are shown in grey and pink ribbon conformation. (A) Anion-π triplet at active site 
shown in green and another triplet in red. Single anion-π pairs shown in blue and pink. Substrate 
dTDP bound in the active site shown in space-filling configuration. (B) Distance vs Time and (C) 
Angle vs Time plots for the seven intramolecular anion-π pairs only seen during the MD 
simulation.  
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Figure 1.2 continued 
A 
B 
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Figure 1.2 continued 
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Figure 1.3. Solvent analysis of anion-π pairs. Total number of water molecules in the region 
between the Phe and anion residues for (A) eight intramolecular anion-π pairs in the crystal 
structure, (B) the two symmetrical pairs present at the dimer interface, and (C) seven 
intramolecular anion-π pairs identified during MD simulations. 
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Figure 1.3 continued 
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Figure 1.3 continued 
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Figure 1.4. Interaction energies of anion-π pairs. Interaction Energy vs Time plots for (A) eight 
intramolecular anion-π pairs in the crystal structure, (B) two symmetrical pairs present at dimer 
interface and (C) seven intramolecular anion-π pairs only seen during the MD simulation.  
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Figure 1.4 continued 
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Figure 1.4 continued 
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Figure 1.5. Angle/distance conformation distributions and free energy (PMF) maps. 
Angle/distance conformation distribution maps and free energy (PMF) maps for (A,B) Phe112-
Asp84, (C,D) Phe33-Glu35 and (E,F) Phe4-Glu3. The angle-distance values in the crystal structure 
are depicted as white dots on the plots. 
 
 
 
 
 
 
 
 
 
 
 55 
 
 
 
 
 
Figure 1.5 continued 
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 Figure 1.5 continued 
C 
D 
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Figure 1.5 continued 
E 
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Figure 1.6. Anion-π network. The two monomers are shown in grey and pink ribbon 
conformation. (A) Intrarmolecular cluster in two monomers in green and intermolecular cluster at 
dimer interface in orange, connected together by single anion-π pairs shown in blue that are only 
seen during the MD simulation. Substrate dTDP bound in the active site shown in space-filling 
configuration. (B) The complete anion-π network over the two monomers.  
A 
B 
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Figure 1.S1. Spherical coordinates in space. Spherical coordinates in space (r, θ, φ): radial 
distance r, polar angle θ (theta), and azimuthal angle φ (phi).  
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Figure 1.S2. Randomly distributed points on unit sphere. Distribution of 1 million randomly 
distributed points on a unit sphere at polar angles: 0 to 180°. Each point on the plot represents the 
distribution in a 5 degree interval. The resulting distribution is Gaussian. 
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Figure 1.S3. Randomly distributed points at different distances. Distribution of points with 
same probability density function and at different distances (different sphere radii). The area of 
sphere (and solid angle) ∝ R2. Accordingly, the resulting distribution is exponential. 
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Figure 1.S4. RMSD for protein backbone. RMSD plot for the protein backbone over the time 
course of the trajectory. 
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Figure 1.S5. Sidechain conformations sampled by anion-π pairs present in crystal structure . 
Sidechain conformations sampled by the ten anion-π pairs present in the crystal structure, in the 
MD snapshots showing minimum and maximum angles for each pair (Table 1.2).  
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Figure 1.S6. Distances and angles of anion-π pairs in crystal structure. (A) Distance vs Time 
and (B) Angle vs Time plots for the eight intramolecular anion-π pairs in the crystal structure. (C) 
Distance vs Time and (D) Angle vs Time plots for the two symmetrical pairs present at the dimer 
interface.  
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Figure 1.S6 continued 
A 
 66 
 
 
 
 
 
Figure 1.S6 continued 
B 
C 
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Figure 1.S7. Sidechain conformations sampled by anion-π pairs seen during MD simulation. 
Sidechain conformations sampled by the seven anion-π pairs only seen during the simulation, in 
the MD snapshots showing minimum and maximum angles for each pair (Table 1.3). 
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Figure 1.S8. Solvent molecules around anion-π pairs. Total number of water molecules within 
4 Å  of center of mass of Phe and center of charge of the anion for (A) eight intramolecular anion-
π pairs in the crystal structure, (B) the two symmetrical pairs present at the dimer interface and (C) 
seven intramolecular anion-π pairs identified during MD simulations. 
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Figure 1.S8 continued 
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Figure 1.S8 continued 
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Figure 1.S9. Angle/distance conformation distribution and free energy (PMF) maps. 
Angle/distance conformation distribution maps and free energy (PMF) maps for the remaining 
anion-π pairs. The angle-distance values in the crystal structure are depicted as white dots on the 
plots. 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Figure 1.S9 continued 
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Chapter 2  
STRUCTURAL AND FUNCTIONAL EVIDENCE 
FOR TESTOSTERONE ACTIVATION OF 
GPRC6A 
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Abstract 
GPRC6A is a multi-ligand G-protein coupled receptor (GPCR) that is activated by cations, 
L-amino acids, and osteocalcin. GPRC6A plays an important role in the regulation of testosterone 
(T) production and energy metabolism in mice.  T has rapid, transcript ion-independent (non-
genomic) effects that are mediated by a putative GPCR.  We previously found that T can activate 
GPRC6A in vitro, but the possibility that T is a ligand for GPRC6A remains controversial.  Here, 
we demonstrate direct T binding to GPRC6A by competitive binding assays and construct 
computational structural models of GPRC6A to identify potential binding poses of T.  The 
modeled binding was confirmed by mutagenesis.   Using Gpr6ca-/- mice, we define several 
biological functions regulated by GPRC6A-dependent T rapid signaling, including T stimula t ion 
of insulin secretion in pancreatic islets and enzyme expression involved in the biosynthesis of T in 
Leydig cells. Together our data show that GPRC6A directly mediates the rapid signaling response 
to T and uncovers previously unrecognized endocrine networks.  
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Introduction 
Classically, testosterone (T) stimulates target gene expression through the nuclear 
androgen receptor (AR).  T is converted by 5-reductase to dihydrotestosterone (DHT).  DHT 
binds with high affinity to AR to form a transcription factor complex that translocates to the 
nucleus to activate androgen-responsive genes.  Emerging clinical observations indicate that 
conversion of T to DHT is not obligatory and that T has clinically important functions distinct 
from activation of AR-mediated gene transcription in some tissues. T also elicits rapid, 
transcription- independent signaling responses, such as activation of ERK1/2, through a putative 
membrane G-protein coupled receptor (GPCR).  The identity of this T-sensing GPRCR is not 
known and its physiological significance remains uncertain (1).   
GPRC6A is a member of the class-C GPCR family (2-4), which includes the calcium 
sensing receptor (CasR).   Like CasR, GPRC6A is activated by cations and L-amino acids; 
however, the physiological ligand for GPRC6A is thought to be the bone-derived hormone 
osteocalcin (Ocn) (5-7).  Both GPRC6A and Ocn are involved in the regulation of energy 
metabolism and T production in mice (8-10), and Gprc6a-/- and Ocn-/- mice are phenocopies (6,11).  
GPRC6A is widely expressed, including β-cells, bone marrow stromal cells, monocytes, prostate 
cancer cells, skeletal muscle cells,  keratinocytes, and Leydig cells, as well as other tissues known 
to be targeted by T (11-16).  GPRC6A is also a candidate for this T-sensing GPCR (12,17).   In 
this regard, overexpression of GPRC6A imparts the ability of extracellular T to illicit a rapid 
signaling response in HEK-293 cells, which lack the AR.  Moreover, GPRC6A loss-of-func tion 
attenuates T stimulated rapid signaling in multiple tissues. Indeed, T rapid signaling is inhibited in 
bone marrow stromal cells derived from Gprc6a−/− mice and in 22Rv1 prostate cancer cells after 
siRNA-mediated knockdown of GPRC6A.  There is also indirect evidence that T regulates 
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luteinizing hormone secretion (18), stimulates insulin secretion in β-cells, and induces NADPH 
oxidase isozymes in keratenocytes (17) through GPRC6A (9).    
The role of GPRC6A in mediating the effects of T remain controversial, because the 
binding sites for T in GPRC6A have not been identified, some studies have failed to confirm T-
activation of GPRC6A in vitro (19), and the physiological roles of T activation of GPRC6A have 
not been directly demonstrated.  Indeed, the global Gprc6a-/- mouse phenotype is complex and has 
multiple hormonal abnormalities that might indirectly account for the effects attributed to T-
activation of GPRC6A (11).  To examine direct T binding to GPRC6A we have performed  
competitive binding assays. Furthermore, we have constructed computational structural models of 
GPRC6A to identify potential binding poses of T, which enabled confirmatory mutagenes is 
experiments to be performed.  Finally, we directly demonstrate the role of GPRC6A in mediating 
T effects in regulating β-cell and Leydig functions in cells derived from Gprc6a-/- mice. 
 
 
Materials and Methods 
Animals 
Generation of global Gprc6a-/- mice has been previously reported (11).  Mice were 
maintained and used in accordance with recommendations as described (National Research 
Council. 1985; Guide for the Care and Use of Laboratory Animals DHHS Publication NIH 86-23, 
Institute on Laboratory Animal Resources, Rockville, MD) and following guidelines established 
by the University of Tennessee Health Science Center Institutional Animal Care and Use 
Committee. The animal study protocol was approved by the institutional review board at 
University of Tennessee Health Science Center Institutional Animal Care and Use Committee.  
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Reagents and antibodies 
Insulin (Mouse) Ultrasensitive ELISA kit and mouse C-peptide ELISA kit were obtained 
from ALPCO Diagnostics. T, glucose and insulin were purchased from Sigma. 
 
Cell culture 
All culture reagents were from Invitrogen. Human embryonic kidney HEK-293 cells were 
obtained from American Type Culture Collection. HEK-293 cells stably transfected with 
pcDNA3.mGPRC6A were created as previously described (12,20). 
 
Mouse islets isolation and ligand stimulation 
Primary islets were isolated using modified method as described (21,22). Briefly, after 
dissection and mincing, pancreata were digested with 3 ml/pancreas of a collagenase P (1 mg/ml; 
Roche) solution in complete HBSS (HBSS 1× supplemented with 20 mM Hepes, pH 7.4, and 2 
mM CaCl2) for 15 minutes in a 37 oC shaking water bath. Islets were subsequently purified through 
a Histopaque 1083 density centrifugation (Sigma). After centrifugation, the islet layer was 
transferred into petri dishes with wash buffer (HBSS with 10 mM Hepes and 1% FBS; Invitrogen), 
then handpicked, and cultured in low-glucose medium (RPMI 1640 with 5.6 mM glucose; 
Invitrogen) for 1 h before being treated for 1 h with T (80 nM). The insulin stimulation index (SI) 
was calculated as the ratio of media insulin concentrations in T or Ocn divided by the insulin 
concentration in low glucose conditions.  
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Real time RT-PCR 
For quantitative real-time RT-PCR assessment of insulin and glucagon gene expression, 
we isolated total RNA from the islets or pancreas or other tissues of control and Gprc6aβ-cells cko 
mice by standard TRIzol method (Invitrogen) and reverse transcribed 2.0 µg of total RNAs using 
cDNA synthesis kit (Bio-Rad). PCR reactions contained 100ng of template (cDNA or RNA), 
300nM each of forward and reverse primer, and 1× iQ SYBR Green Supermix (Bio-Rad) in 50µL. 
Samples were amplified for 40 cycles in an iCycler iQ Real-Time PCR Detection System (Bio-
Rad) with an initial melt at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds 
and 60°C for 1 minute. PCR product accumulation was monitored at multiple points during each 
cycle by measuring the increase in fluorescence caused by the binding of SybrGreen I to dsDNA. 
The threshold cycle (Ct) of tested-gene product from the indicated genotype was normalized to the 
Ct for cyclophilin A. The primers for mouse cytochrome P450, family 17, subfamily a, polypeptide 
1 (cyp17a1) consisted of mCyp17a.F56: agtcaaagacacctaatgccaag and mCyp17.R138: 
acgtctggggagaaacggt; for cytochrome P450, family 11, subfamily a, polypeptide 1 (cyp11a1) 
consisted of mCyp11a.F127: aggtccttcaatgagatccctt and mCyp11a.R263: tccctgtaaatggggcca tac ; 
and for the cyclophilin A consisted of cyclophilin A.For: ctgcactgccaagactgaat and cyclophil in 
A.Rev: ccacaatgttcatgccttct. Dissociation analysis was used to confirm the presence of a single 
transcript and the lack of primer-dimer amplification in all PCR reactions. 
 
Saturation analysis of [3H]T binding in HEK-293 cells expressing GPRC6A 
Cells were dislodged from tissue culture plates by using a rubber policeman and crude 
membranes were prepared by Dounce homogenization in 50 mM Tris-HCl pH 7.4 at 25ºC with 
120 mM NaCl, 1 mM EDTA, 10 mM MgCl2 and a protease inhibitor cocktail for mammalian 
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tissue culture containing 104 mM AEBSF, 80 µM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 
mM pepstatin A and 1.4 mM E-64.  The homogenate was subjected to centrifugation at 14,000 x 
g for 10 minutes and the resulting crude total cellular pellet was resuspended in the buffer above.  
The membranes were either used immediately for binding or flash frozen at -70º C.  The membrane 
protein concentration was quantified by the method of Bradford, using BSA as the protein standard 
(23).   
For saturation analysis of [3H]T, a range from 0-20 nM [3H] T was used.  Routinely, 50-
75 ug of membrane protein was used per tube, and the analysis was performed in triplicate. The 
buffer consisting of 120 mM NaCl, 1 mM EDTA, 10 mM MgCl2 was used as the binding and wash 
buffer and varying concentrations of [3H]T was added and allowed to incubate for 2 hours at 
ambient room temperature with agitation.  Non-specific ligand binding was determined by the 
inclusion of 200 nM cold T to a parallel set of tubes. The reactions were terminated by dilut ion 
with ice cold buffer and filtration through GF/C glass fiber membranes to retain bound ligand.  The 
retained radioactivity was quantified by liquid scintillation counting.  
For saturation analysis of [3H]T binding in the presence of Ca2+, 3mM CaCl2 was added to binding 
and wash buffer and the assays performed as described.  
The saturation data was analyzed using Graphpad Prism 6.0.  For analysis of best fit, an 
extra sum of squares F test was performed to determine if a one site with hill slope or two site fit 
was superior for the saturation data.  
For competition analysis, a concentration of 1nM [3H]T was used, with a concentration of 
50-75 µg of cell membrane per tube.  The analysis was performed in triplicate. L-Arginine (0-50 
mM), or osteocalcin (0-50 µg/ml) were added to the assays and the incubations continued for 2 
hours at ambient temperature.  The assays were terminated by dilution with ice cold buffer and 
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filtration through GF/C glass fiber membranes and the retained radioactivity quantified by liquid 
scintillation counting. Non-specific binding was determined by the addition of 200 nM cold T.  
The data was analyzed by Graphpad Prism 6.0.  
 
GPRC6A homology modeling 
Multiple sequence alignment (MSA) of the GPRC6A sequence with eight family-C 
sequences was performed using MAFFT (Multiple Alignment using Fast Fourier Transform) 
sequence alignment and the EINSI alignment method (24). The family-C sequences used are: 1) 
human calcium-sensing receptor, 2) human probable G-protein coupled receptor-158, 3) human 
retinoic acid-induced protein-3, 4) human taste receptor type-1 member-1, 5) human metabotropic 
glutamate receptor-1 (PDB code 4OR2), 6) human metabotropic glutamate receptor-5 (PDB code 
4OO9), 7) mouse metabotropic glutamate receptor-3 (PDB code 2E4U), and 8) human gamma-
aminobutyric acid B receptor-1 (PDB code 4MQE). Sequences 1 through 4 have no available 
crystal structure, whereas sequences 5 and 6 have crystal structures for their transmembrane 
domains, and sequences 7 and 8 have crystal structures for their extracellular domains. In addition, 
the MAFFT multiple sequence alignment also included seven family-A sequences, which are 
closest in sequence identity with family-C GPCR’s, with existing crystal structures of the short 
extracellular domain, transmembrane domain and short cytoplasmic domain. These sequences 
were: bovine rhodopsin receptor (PDB code 3CAP), turkey beta-1 adrenergic receptor 2VT4), 
human beta-2 adrenergic receptor (PDB code 2RH1), human adenosine A2A receptor (PDB code 
2YDV), human 5-hydroxytryptamine receptor-2B (PDB code 4IB4), human 5-hydroxytryptamine 
receptor-1B (PDB code 4IAR) and rat neurotensin receptor type-1 (PDB code 4GRV).  
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From the MSA results, the structures of the mGlu-1 and mGlu-5 receptors (with crystal 
structures of transmembrane domains) were selected as templates for the transmembrane domain 
modelling. Missing regions in the cytoplasmic loop-2 (seq 688-691) and C-terminus (seq 844-845) 
of the mGluR-1 template structure were modelled using mGluR-5, and missing regions in the 
cytoplasmic loop-2 (seq 683-688) and the extracellular loop-2 (seq 721-728) of mGluR-5 template 
structure were modelled using mGluR-1. Ten main chain models with ten sidechain conformers 
per mainchain model were generated for each template using the MOE-2012 (Molecular Operating 
Environment, 2013.08; Chemical Computing Group Inc.) homology modeling facility with the 
CHARMM27 force-field (25). The GPRC6A homology models were validated using PolyPhobius 
(26). The best-scoring homology models; one from using mGluR-1 as a template and one from 
using mGluR-5 as a template, were selected for docking studies based on their predicted GB/VI 
scores (27), that rank the models based on Coulomb and Generalized Born interaction energies. 
 
Identification of ligand binding sites in GPRC6A models  
The recently published crystal structures of mGluR-1 and mGluR-5 contain negative 
allosteric modulators bound (28,29). The allosteric binding-site residues for these two receptors 
and the respective CasR and GPRC6A residues in the MSA are listed in Tables 1 and 2. In this 
site, Gly-667, Ser-669, Trp-795, Phe-798 and Tyr-802 in GPRC6A are found to be conserved 
between all the four receptors, with conserved or chemically similar residues also present for 
residues Phe-650, Phe-666, Cys-673, Phe-752, Met-755, Leu-756, Ala-763, Ala-794, Ile-818 and 
Ile-825. 
A number of agonists/antagonists have been reported for the closest family-C member, 
CasR, that bind to the transmembrane domain of the receptor (38). All residues involved in binding 
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in CasR identified by mutagenesis experiments (Ser-657, Phe-668, Arg-680, Phe-684, Phe-688, 
Leu-773, Leu-776, Trp-818, Phe-821, Glu-837, Ile-841) are conserved in GPCR6A except Ser-
657, Leu-773 and Leu-776, which are replaced by Cys-639, Phe-752 and Met-755, respectively. 
CasR calcimimetic calindol and the calcilytic NPS2143 have been found to antagonize mouse -
GPRC6A (28). The binding site residues for these antagonists in mouse-GPRC6A found by 
mutagenesis experiments (Phe-666, Phe-670, Trp-797, Glu-816) are conserved in both human-
GPRC6A and CasR. Several 2-phenyl-indole derived allosteric antagonists have also been 
reported in mouse-GPRC6A that are selective only for this receptor among the family-C family 
receptors (7). The possible binding site residue reported for these antagonists in mouse-GPRC6A 
(Ile-759) is conserved in human-GPRC6A and not conserved in CasR (Thr-780), mGluR-1 (Asn-
760) or mGluR-5 (Asn-747). 
The above binding site information from both conservation of residues in the MSA and the 
mutagenesis experiments was used for identifying binding sites in GPRC6A used in the present 
docking studies.  
 
Docking of T  
Docking of T to the transmembrane domain of the selected GPRC6A homology models 
was carried out using MOE-2012’s Docking facility with the CHARMM27 force-field. CHARMM 
parameters for the ligands were generated by MOE from a fragment-based approach. The binding 
site was defined in MOE from the binding-site residues described above using MOE’s Site Finder 
facility. Binding site residue side-chains were allowed to be flexible during the docking using a 
tethering weight of 0.1. London dG free energy scores were used to rank poses of the docked 
ligand (36). Potential hydration sites were calculated in the binding sites of both homology models 
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using the MOE’s Solvate facility. Water molecules are predicted to be potentially present in both 
homology models’ binding sites, which were only implicitly included in the docking calculations.  
 
Measurement of cAMP accumulation 
 HEK-293 and HEK-293 transfected with mouse GPRC6A cDNA cells  (105 cells/we ll) 
(12) were cultured in triplicate in 12-well plates in DMEM supplemented with 10% fetal bovine 
serum and 1% P/S (100 units/ml of penicillin and 100 ug/ml of streptomycin) for 48 hours followed 
by overnight incubation in DMEM/F12 containing 0.1% BSA to achieve quiescence.  Quiescent 
cells were treated with vehicle control, 40 nM T or 60 ng/ml bovine osteocalcin (Ocn) or 40 nM T 
and 60 ng/ml Ocn together for 30 minutes at 37 °C. Then the reaction was stopped and the cells 
lysed with 0.5 ml 0.1 N HCl. cAMP levels were measured by using Cyclic AMP EIA kit (Cayman 
Chemical, Ann Arbor, MI) following the manufacture’s protocol. 
 
Leydig cells isolation 
To isolate Leydig cells from wild type and Gprc6a-/- mice, the testes from 10~12 week-old 
mice were obtained and enzymatically dispersed with the method as previously described (30). 
Briefly, the testes from wild type and Gprc6a-/- mice were decapsulated and dispersed with 0.25 
mg/ml collagenase (Invitrogen) in medium 199 for 10 min at 4oC with 70~90 rpm shaking. The 
separated cells were filtered through 100 nm filter, centrifuged at 250 X g and resuspended in 55% 
isotonic Percoll (Sigma). Following density gradient centrifugation at 25 000 X g for 45 min at 
4oC, the PLC fraction was collected between densities of 1.064 and 1.070 g/ml. The cells were 
washed with HBSS (5 time of volume; Invitrogen), centrifuged at 250 X g and The cells were 
washed with HBSS (5 time of volume), centrifuged at 250 X g and resuspended in phenol red-free 
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medium (DMEM/Ham’s F-12, D-2906, Sigma) supplemented with 1 mg/ml bovine serum albumin 
(BSA).  
 
Statistics 
 We evaluated differences between groups by one-way analysis of variance, followed by a 
post-hoc Tukey's test. Significance was set at p<0.05. All values are expressed as means ± SEM.  
All computations were performed using the Statgraphic statistical graphics system (STSC Inc.). 
 
Results 
Binding of T to GPRC6A 
To examine whether T binds to GPRC6A, we performed saturation analysis of [3H]T 
binding in HEK293 cells overexpressing GPRC6A (Figure 1A).  We found that T binds to 
GPRC6A with a Kd for [3H]T of 9.5 ± 2.41 nM (n=5) in the absence of added calcium (control) 
(Figure 1A), with the data best fitting a model with a Hill slope of 1.9 ± 0.25.  GPCRC6A is known 
to be activated by calcium (7,31).  Adding 3mM calcium resulted in a shift in the Kd of [3H]T to 
7.7 ± 1.7 nM  with a Hill slope of 1.17 ± 0.13 (n=4) (Fig 1A).  Ocn also activates GPRC6A (10,14).  
Interestingly, Ocn (40 ng/ml) shifted the Kd for [3H]T to 3.3 ± 0.5 nM, with a Hill slope  of 1.5 ± 
0.2 compared to 9.8 ± 1.7 nM with a hill slope  of 2.0 ± 0.2 in the controls (n=3) (Figure 1B). 
These data indicate that T binds to GPRC6A and this interaction is modulated by calcium and Ocn. 
 
Computational modeling of T binding to GPRC6A 
To investigate the molecular basis for T binding to GPRC6A (9,32), structural models of 
GPRC6A were constructed and used to identify potential T binding poses.   The GPRC6A 
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homology models developed are shown in Figure 2.  Helix regions in multiple sequence alignments 
are highly conserved among GPCRs, whereas the loop regions exhibit low sequence similarity, as 
shown in Figure 2A. The GPRC6A sequence exhibits a similarity of 43.2% and 44.7% to the 
mGluR-1 and mGluR-5 receptors respectively, the only sequences for which crystal structures of 
the transmembrane domain exist (sequence-2 and sequence-3 in Figure 2B). These receptor 
structures were selected as templates for the homology modeling calculations and the 
corresponding structural models selected for docking studies.  
The highest scoring models are shown in Figure 2C and 2D. These models exhibit very 
similar structures, with a root mean square deviation (RMSD) of ~4 Å2 between the backbone 
atoms. These models were validated against Hidden Markov secondary structure predictions 
generated by PolyPhobius, and found to be consistent (Table 3 and 4), with only one loop region 
and one transmembrane helix in the homology models exhibiting deviation from the PolyPhobius -
predicted structure for five or more residues.  
 
Docking of Testosterone 
Next, we docked T to the above homology models as described in the Methods. The 
binding sites found in the mGluR-1 and mGluR-5 based models of GPRC6A are shown in Figure 
3A and B respectively. The docking scores and the binding pocket residues in these sites are listed 
in Table 5 for the top-ranking binding poses of T. Thirteen residues in the mGluR-1 model, and 
twelve in mGluR-5 were identified as possibly interacting with T. In both homology models, the 
hydrophobic core of T is surrounded by aliphatic side-chains and/or aromatic Phe (F), Trp (W) or 
Tyr (Y) residues. The hydroxyl and carbonyl moieties of T are located in hydrogen bond acceptor-
rich regions, either on side chains or on the backbones of residues in the binding pocket.  Six of 
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these predicted binding residues are found in both models, including F-666, F-670, F-752, M-755, 
L-756 and L-759 (Fig 2 and Table 5). 
 
Validation of T-binding and computational model by mutagenesis 
To validate the binding model, we compared the T activation of wild-type and mutant 
GPRC6A transfected into HEK-293 cells.  We observed a dose-dependent effect of T to stimulate 
cAMP accumulation (Figure 4A) and ERK phosphorylation (Figure 4B) in HEK-293 cells 
transfected with wild-type GPRC6A.  A significant response was observed at 5 nM and a maximal 
response at a T concentration of 60 nM, using cAMP accumulation as the read out (Figure 4A).  
No response to T is observed in non-transfected HEK-293 cells in ERK phosphorylation (Figure 
4B low panel).  Consistent with prior reports (13,14), L-Arginine (L-Arg) (20 mM) stimulated 
cAMP to a similar magnitude as T in HEK-293 cells expressing GPRC6A but not in untransfected 
HEK-293 cells (Figure 4C).   We also found that the protein kinase A (PKA) inhibitor, H89, 
blocked GPRC6A-mediated T stimulated ERK phosphorylation (Figure 4D), indicated that PKA 
is involved in the GPRC6A signaling pathway. 
To validate the computational modeling of T binding to GPRC6A, we mutated Phe-666 
(F-666) (Fig 2 and Table 5) into alanine by site-directed mutagenesis to investigate its possible 
interaction with T (33). The Phe-666-Ala (F666A) mutant and the wild type mGPRC6A were 
transiently transfected into HEK293 cells.  Expression of the wild-type and F666A mutant 
GPRC6A receptors was assessed by Western blotting using a Myc antibody, which recognized the 
Myc epitope located at the amino-terminal tail of the WT and mutant receptors (33). Expression 
of the F666A mutant receptor was comparable to that of the WT receptor (Figure 4E, right panel). 
However, the F666A mutant showed a significant and reproducible decrease in the ERK 
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phosphorylation compared to that of WT receptor in transfected HEK293 cells (Figure 4E, left 
panel), thus validating the computational model. 
 
Loss of T responses in Gprc6a-/- mice 
To evaluate the role of GPRC6A in sensing T in vivo, we examined Egr-1 expression in 
the pancreas and testis of Gprc6a-/- mice and wild-type littermates after the administration of 200 
mg/kg T by intraperitoneal injection. We found that T administration significantly increased Egr-
1 expression in the pancreas and testis of wild-type mice, whereas Gprc6a-/- mice showed no 
response to T (Figure 5A).  
To test this biological response ex vivo, we examined the effect of GPRC6A activation in 
isolated islets and Leydig cells from wild-type and Gprc6a-/- mice.  We found that T increased the 
insulin stimulation index in islets isolated from wild-type but not Gprc6a-/- mice (Figure 5B).   
Next, we confirmed that GPRC6A is expressed in β-cells.  We found that Gprc6a transcripts were 
present in INS-1 rat β-cell line  (Figure 5C) (34). In addition, we observed a dose-dependent effect 
of T to stimulate insulin secretion in INS-1 β-cells (Figure 5D).   Finally, we found that 100 nM T 
significantly stimulated T biosynthesis enzymes, cholesterol side-chain cleavage enzyme 
(Cyp11a) and steroid 17-alpha-monooxygenase (Cyp17a) expression in Leydig cells from wild-
type mice but not in Gprc6a-/- mice (Figure 5E).    
 
Discussion 
The diverse ligand specificity of GPRC6A and the lack of understanding of the structural 
basis for ligand/receptor interactions have resulted in controversy regarding the possibility that 
GPRC6A functions as a T-sensing GPCR (12,32).  In the current study, we showed that T 
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specifically binds to GPRC6A using [3H]T radioligand binding assays and provided a structural 
model in which T binds to the heptahelical domain of GPRC6A.  Mutagenesis of a critical T 
binding site identified in this model inhibited T activation of GPRC6A in vitro, confirming the 
model.  Finally, we showed that T activates GPRC6A signaling in vitro and in vivo, leading to 
regulation of insulin secretion by -cells and enzymes controlling T production by Leydig cells.  
Collectively, these data indicate that GPRC6A is a T-sensing receptor that mediates the non-
classical, rapid membrane signaling responses to T. 
Our computational model of GPRC6A suggests that the binding pocket for T corresponds 
to the common allosteric site for Class C GPCRs.  Residues in GPRC6A predicted to be involved 
in docking T, include Phe-666, Phe-670, Phe-752, Met-755, Leu-756, Ile-759, Ala-794, Trp-795, 
Phe-798, Glu-814 and Ile-818.  Previous mutagenesis-based studies of Class C GPCR allosteric 
sites showed that positions of the T binding-pocket residues have also been implicated in the 
binding of mGluR-1, mGluR-5, and CasR allosteric modulators (Table 1 and 2).  Here, we have 
confirmed the importance of the Phe-666 in T activation of GPRC6A by mutagenesis studies; 
substitution of Phe-666 with Ala resulted in marked attenuation of T activation of the mutant 
GPRC6A compared to the wild-type receptor.   Phe-666 also overlaps the site for the calcimimetic 
and calcilytic binding to the closely related calcium sensing receptor, CasR (33).  Calcimimetics 
and calcilytic also respectively stimulate and antagonize mouse-GPRC6A (7,33).  Other residues 
identified in the model are candidates for additional directed mutagenesis studies to confirm their 
role in T-binding and activation of GPRC6A.  Antagonists may also interact with this binding site 
in GPRC6A (35).  Of note, the 2-phenyl-indole derived allosteric antagonist, which is specific for 
only GPRC6A among the class-C GPCR's, is found to interact with Ile-759. This residue is not 
conserved in other class-C GPCR's, and may be important in conferring specificity to this receptor.  
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Thus, this site could potentially control the binding of a number of different allosteric modulators 
(antagonists and agonists) of GPRC6A. Future molecular dynamics computer simulations of the 
models, followed by selection of representative protein conformers and ensemble-docking of 
ligands in the snapshots, while computationally expensive, will likely be able to identify the most 
stable binding modes of ligands in GPRC6A and allow a detailed structure-based description of 
binding poses (36), as well as  identification of novel small molecules that selectively modulate 
GPRC6A.  
The identification of the GPCR mediating the rapid response to T now permits us for the 
first time to identify the physiological processes regulated by this T-sensing GPRC and to 
distinguish these from the functions of the androgen receptor (AR).  In the current studies, we 
show that GPRC6A is an important G-protein coupled receptor for T signaling in β-cells.  In this 
regard, T dose-dependently stimulated insulin secretion in INS-1 cells and activated cAMP-
dependent pathways in HEK-293 cells expressing GPRC6A.  More importantly, T administra t ion 
stimulated rapid Egr-1 signaling in the pancreas of wild-type mice, but this response was lost in 
the pancreas of Gprc6a-/- mice.  Pancreatic islets from Gprc6a-/- mice had a diminished insulin 
secretion index.   The direct regulation of insulin secretion and β-cell proliferation by GPRC6A 
raises the possibility of a link between T, male puberty and β-cell mass.  Although increased β-
cell mass with an accelerated rate of somatic growth of adolescence has not been identified (37), 
T  has been shown to protect against glucotoxicity-induced apoptosis of pancreatic β-cells (38) 
and  T deficiency can  contribute to the development of  metabolic syndrome  (39).  Our data 
suggest that some of  the protective effect of T on pancreatic β-cell mass and insulin secretion 
could be mediated by GPRC6A, in addition to androgen receptor-mediated mechanisms (39). 
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We also showed here that T activates GPRC6A in Leydig cells. Isolated Leydig cells from 
Gprc6a-/- mice exhibited diminished expression of the T-stimulated Cyp11a and Cyp17a, which 
regulate T biosynthesis. In addition, T stimulated rapid Egr-1 signaling in the testes of wild-type 
mice, but not in the testes of Gprc6a-/- mice, indicating that loss-of-GPRC6A disrupts a putative 
autocrine positive feedback loop whereby T regulates its own production.  Our observation could 
account for the heretofore unexplained finding that testicular interstitial fluid has effects on Leydig 
cell testosterone secretion that are independent of LH and hCG (40), as well as the finding that 
Leydig cell production of T and Cyp17a expression are unaffected by the loss of AR (41).  T 
activation of T production through GPRC6A is also consistent with the actions of another 
GPRC6A ligand, Ocn, to stimulate T production (12,14). 
            Other studies have shown that GPRC6A is important in prostate cancer.  GPRC6A is 
increased in prostate cancer cells and is linked to prostate cancer progression in genome wide 
associative studies (13,42).  Ablation of GPRC6A attenuates prostate cancer progression in a 
mouse model (13), suggesting that the AR-independent effects of T in resistant prostate cancer 
might be mediated by GPRC6A.  GPRC6A has also been shown to mediate the functional response 
to T in skin keratinocytes (17).   
            The fact that GPRC6A is also expressed in liver, adipocytes, muscle, skin, and bone, as 
well as other tissues, and is activated by T, as well as multiple structurally distinct ligands, predict 
additional metabolic functions and integration of endocrine networks involving multiple organs.  
Indeed, global Gprc6a-/- mice, in addition to abnormalities of β-cells, Leydig cells, and prostate, 
also have abnormalities in hepatic, bone, muscle and adipocyte function.  Since GPRC6A and AR 
are also co-expressed in many of these tissues, there may be other organs where differences in 
rapid and classical T effects may be physiologically important.  Interestingly, consistent with AR-
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independent effects of T that are mediated through GPRC6A,  recent clinical studies show that 
-reductase inhibitor has 
effects on lean body and muscle mass, sexual functions, hematocrit, cholesterol and other 
biological effects that are consistent with the predicted functions of GPRC6A derived from the 
phenotype of Gprc6a-/- mice (43).   
In conclusion, an understanding of the tissue specific functions of GPRC6A and the 
structural basis for its binding to distinct ligands is revealing new connections between endocrine 
networks that heretofore were not thought to be related.  Future studies that conditionally delete 
GPRC6A and AR in these and other tissues are now possible to differentiate between GPRC6A 
and AR in mediating T functions. The structural modeling presented here also represents a first 
step towards developing agonists and antagonists for this novel druggable target.  
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Table 2.1. mGluR-1 allosteric binding site residues for negative allosteric modulator 
(antagonist) and alignment with other receptors (28,29). mGlu1 and CasR residues with ‘*’ 
shown to be important for binding allosteric modulators by mutagenesis experiments. GPRC6A 
residues with ‘*’ show reduced binding affinity for allosteric modulators by mutagenes is 
experiments in mouse-GPRC6A and are conserved in human-GPRC6A.  
 
mGlu1 
Numbering 
mGlu
1 
mGlu5 CasR GPRC6
A 
Consensus  (% 
similarity) 
Conservati
on (% 
identical) 
648 L L-635 F-668* F-650 100 (nonpolar) 50 (L,F) 
660 Q Q-647 R-680* R-662 50 (polar/charged) 50 (Q,R) 
661 R R-648 Q-681 Q-663 50 (charged/polar) 50 (R,Q) 
664 V I-651 F-684* F-666* 100 (nonpolar) 50 (F) 
668 S* P-655 F-688* F-670* 75 (nonpolar) 50 (F) 
748 T T-735 E-767 E-746 50 (polar/charged) 50 (T,E) 
753 V V-740 L-773* F-752 100 (nonpolar) 50 (V) 
756 P* P-743 L-776* M-755 100 (nonpolar) 50 (P) 
757 L* L-744 I-777 L-756 100 (nonpolar) 75 (L) 
760 N* N-747 T-780 I-759* 75 (polar) 50 (N) 
761 G G-748 C-781 A-760 75 (nonpolar) 50 (G) 
794 T T-781 F-814 Y-791 75 (polar) 50 (T) 
797 I I-784 V-817 A-794 100 (nonpolar) 50 (I) 
798 W* W-785 W-818* W-795* 100 (nonpolar) 100 (W) 
801 F* F-788 F-821* F-798 100 (nonpolar) 100 (F) 
805 Y* Y-792 Y-825 Y-802 100 (polar) 100 (Y) 
811 K K-798 V-833 V-810 50 (charged/nonpolar) 50 (K,V) 
812 I I-799 S-834 P-811 75 (nonpolar) 50 (I) 
815 T* M-802 E-837* E-814* 50 (charged) 50 (E) 
818 A* S-805 A-840 V-817 75 (nonpolar) 50 (A) 
822 S S-809 A-844 S-821 75 (polar) 75 (S) 
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Table 2.2. mGluR-5 allosteric binding site residues for negative allosteric modulator 
(antagonist) and alignment with other receptors (28,29). mGlu5 and CasR residues with ‘*’ 
shown to be important for binding allosteric modulators by mutagenesis experiments. GPRC6A 
residues with ‘*’ show reduced binding affinity for allosteric modulators by mutagenes is 
experiments in mouse-GPRC6A and are conserved in human-GPRC6A. 
 
mGlu5 
Numbering 
mGlu
5 
mGlu
1 
CasR GPRC6
A 
Consensus  (% 
similarity) 
Conservatio
n (% 
identical) 
624 G G-637 S-657* C-639 50 (nonpolar/polar) 50 (G) 
625 I I-638 L-658 H-640 75 (nonpolar) 50 (I) 
628 G G-641 C-661 N-643 50 (nonpolar/polar) 50 (G) 
651 I* V-664 F-684* F-666* 100 (nonpolar) 50 (F) 
652 G G-665 G-685 G-667 100 (nonpolar) 100 (G) 
654 S S-667 S-687 S-669 100 (polar) 100 (S) 
655 P* S-668 F-688* F-670* 75 (nonpolar) 50 (F) 
658 S* C-671 C-691 C-673 100 (polar) 75 (C) 
659 Y* Y-672 I-692 I-674 50 (polar/nonpolar) 50 (Y,I) 
740 V V-753 L-773* F-752 100 (nonpolar) 50 (V) 
743 P P-756 L-776* M-755 100 (nonpolar) 50 (P) 
744 L L-757 I-777 L-756 100 (nonpolar) 75 (L) 
747 N* N-760 T-780 I-759* 75 (polar) 50 (N) 
751 I I-764 A-784 A-763 100 (nonpolar) 50 (I,A) 
781 T T-794 F-814 Y-791 75 (polar) 50 (T) 
784 I I-797 V-817 A-794 100 (nonpolar) 50 (I) 
785 W* W-798 W-818* W-795* 100 (nonpolar) 100 (W) 
788 F* F-801 F-821* F-798 100 (nonpolar) 100 (F) 
802 M* T-815 E-837* E-814* 50 (charged) 50 (E) 
805 S* A-818 A-840 V-817 75 (nonpolar) 50 (A) 
806 V V-819 I-841* I-818 100 (nonpolar) 50 (V,I) 
809 S* S-822 A-844 S-821 75 (polar) 75 (S) 
810 A* V-823 S-845 N-822 50 (nonpolar/polar) 25 (A) 
813 A A-826 L-848 I-825 100 (nonpolar) 50 (A) 
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Table 2.3. PolyPhobius secondary structure prediction for GPRC6A sequence. 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Residue Number Structure Prediction 
1-18 SIGNAL PEPTIDE 
 19-592 NON CYTOPLASMIC 
593-616 TRANSMEM 
 617-630 CYTOPLASMIC 
631-651 TRANSMEM 
652-663 NON CYTOPLASMIC 
664-683 TRANSMEM 
684-702 CYTOPLASMIC 
703-727 TRANSMEM 
728-750 NON CYTOPLASMIC 
751-773 TRANSMEM 
774-782 CYTOPLASMIC 
783-804 TRANSMEM 
805-811 NON CYTOPLASMIC 
812-833 TRANSMEM 
834-926 CYTOPLASMIC 
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Table 2.4. Secondary structure features of mGluR-1/mGluR-5 models generated in MOE-2012. * 
indicates the regions that show deviation from predicted structure for 5 or more residues. 
 
Residue 
Number 
 
 
Structure 
1-18 SIGNAL PEPTIDE 
19-591 NON CYTOPLASMIC 
 
592-617 TRANSMEM 
618-633 CYTOPLASMIC 
634-651 TRANSMEM 
652-657* NON CYTOPLASMIC 
658-686* TRANSMEM 
687-703 CYTOPLASMIC 
704-725 TRANSMEM 
726-750 NON CYTOPLASMIC 
 
751-772 TRANSMEM 
773-778 CYTOPLASMIC 
779-804 TRANSMEM 
805-811 NON CYTOPLASMIC 
812-837 TRANSMEM 
838-926       CYTOPLASMIC 
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Table 2.5. Docking scores and binding pocket residues for testosterone binding in GPRC6A 
models generated in MOE-2012. 
 
 
 
 
 
 
 
 
 
C=Cys; R=Arg; Q=Gln; F=Phe; G=Gly; E-Glu; A=Ala; M=Met; L=Leu; I= Ile; Y=Tyr; W=Trp; 
V=Val; S=Ser  
 
 
 
 
 
  
Model Docking 
Score 
Binding Site Residues 
mGluR-1 -11.58 C-659, R-662, Q-663, F-666, G-667, F-670, E-746, 
A-751, F-752, M-755, L-756, I-759, E-814 
mGluR-5 -12.31 F-666, F-670, F-752, M-755, L-756, L-759, Y-791, 
A-794, W-795, F-798, V-817, S-821 
 118 
 
 
Figure 2.1. Evidence for T-binding and activation of GPRC6A.  (A) Saturation analysis of [3H] 
T binding in HEK-293 cells expressing GPRC6A. The figure shows the saturation isotherm of 
[3H] T with or without Ca2+ (A) or with or without Ocn (B).   
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Figure 2.2. GPRC6A Homology Modelling. (A) MSA between 16 sequences shown using 
clustralx color code. Alignment is shown for helix-4, extracellular loop-2 and helix-5 regions. (B) 
Sequence similarity scores between 16 sequences after MSA. Sequence 1: GPRC6A, Sequences 
2-9: class-C GPCR's, Sequences 10-16: class-A GPCR's. mGluR-1 (sequence-2) and mGluR-5 
(sequence-3) taken as main templates for transmembrane domain modelling (C, D) GPRC6A 
transmembrane homology models based on the mGlu-1 and mGlu-5 receptor structures.  
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Figure 2.3. Docking of Testosterone to GPRC6A. (A) (top): Allosteric site in the mGluR-1-
based template model, T is shown in yellow stick representation. (Bottom): Residues surrounding 
T in the binding pocket. (B) (top): Allosteric site in the mGlur-5-based model, T is shown in yellow 
stick representation. (Bottom): Residues surrounding T in the binding pocket. 
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Figure 2.4. Evidence for T activation of GPRC6A. Dose dependent effects of T on cAMP 
response (A) and ERK phosphorylation (B) in HEK293 cells expressing GPRC6A. (C) 
Comparison of cAMP accumulation stimulated by T with other GPRC6A ligands, L-Arginine 
(Arg) in HEK293 cells transfected with and without GPRC6A.  * and ** Significant difference 
from control group and stimulated group at p<0.05 and p<0.01 (n≥4). (D) PKA inhibitor H89 
blocked GPRC6A-mediated ERK phosphorylation stimulation. (F) Functional effect of mutations 
affecting the F666A mGPRC6A residue. HEK293 cells were transfected with the mock plasmid 
or with a plasmid encoding the WT or F666A mGPRC6A mutants. Analysis of mGPRC6A 
expression by Western blot was shown in right panel. Immunoblot analysis of whole cell lysates 
(5 μg proteins) from HEK293 cells transiently transfected with an empty vector (MOCK), or a 
vector containing the WT or the indicated mGPRC6A mutant, was performed following 3~8% 
SDS polyacrylamide gel electrophoresis. Mouse GPRC6A (mGPRC6A) proteins were detected 
using the anti-Myc antibody (Cell signaling). The position of the molecular mass markers is shown 
on the left (kDa). Arrow heads on the right indicate the molecular weight of two major bands 
corresponding to mGPRC6A. Black arrows on the right indicate major bands corresponding to the 
WT and mutant receptors, and white arrow head indicates the dimer of the receptors, respectively.  
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Figure 2.5. β-cell and Leydig cells dysfunction in Gprc6a-/- mice. (A) Effects of systemic 
administration of T on Egr-1 expression in pancreas and testis. T (200 mg/kg) or vehicle was 
injected into mice intraperitoneally, Egr-1 mRNA abundance in various mouse tissue 1 hour after 
injection was determined by real time PCR. Values represent the mean ± SEM. * significant 
difference from control group and stimulated group at p<0.05 (n ≥ 3). (B)  Effects of T on insulin 
stimulation index in islets isolated from wild-type and Gprc6a-/- mice. Values represent the mean 
± SEM. * significant difference from control group and stimulated group at p<0.05 (n ≥ 3). # 
indicates significant different between T treated control group and Gprc6a-/- mice (P< 0.05; n ≥ 
3). (C) RT-PCR analysis showing that Gprc6a message is expressed in INS-1 cells. A similar band 
was observed in rat kidney and pancreas which are known to express GPRC6A. The primers 
sequence are rGPRC6A.For535: aaaatccgctttccttcgttr; and GPRC6A.Rev1400: 
tgggcatcaaaatgaaatgar.   (D)  Effects of T to stimulate insulin secretion in rat β-cells INS-1.  Values 
represent the mean ± SEM.* and ** significant difference from control group and stimulated group 
at p<0.05 and p<0.01 (n=4). (E) Effects of T on message expression of enzymes regulating T 
biosynthesis in isolated Leydig cells. Values represent the mean ± SEM. * significant difference 
from control group and stimulated group at p<0.05 (n ≥ 3). 
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Chapter 3  
NOVEL ALLOSTERIC INHIBITORS OF THE 
PROTHROMBINASE ENZYME COMPLEX 
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Abstract 
The risk of serious bleeding, particularly at high dosage, is a major liability of anticoagulant 
drugs that are active-site competitive inhibitors targeting the Factor Xa (FXa) prothrombin (PT) 
binding site. The present work identifies a new class of anticoagulants that can act as allosteric 
inhibitors of the prothrombinase (PTase) complex composed of FXa and Factor Va (FVa). This 
new class of anticoagulants was identified though an integrated computatio nal/experimenta l 
approach. A 300 ns Molecular Dynamic (MD) simulation of the FXa heavy chain was used to 
identify conformational snapshots representing a structural ensemble sampled by the protein. 
These snapshots were used in ensemble docking calculations of a 281,128 compound drug-like 
subset of the ZINC database against FXa, targeting potential protein/protein interaction sites in the 
FXa-FVa binding interface. From about three million docking calculations, five hundred and 
thirty-five compounds and their structural analogs were selected for experimental validat ion 
through a series of binding and inhibition assays, based on their predicted binding affinities to 
FXa. From these, ten compounds represented by three families of inhibitors were experimenta l ly 
identified that achieve dose-independent partial inhibition of PTase activity in a non-active site 
dependent and self-limiting mechanism. 
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Introduction 
The blood coagulation system represents the first line of defense against blood loss 
following injury.  This system consists of a cascade of circulating inactive serine protease 
zymogens as well as regulatory cofactors and inhibitors.  Each active enzyme, once generated from 
its zymogen, specifically cleaves the next zymogen in the cascade pathway to produce an active 
protease, a process that is repeated until finally thrombin cleaves the fibrinopeptides from 
fibrinogen to produce fibrin which polymerizes to make a blood clot.  The amplification provided 
by this system leads to the potential for explosive clot formation.(1) Although efficient clotting 
limits the loss of blood at a site of trauma, it also poses the risk of systemic coagulation resulting 
in massive thrombosis.  This can result in myocardial infarction, unstable angina, atrial fibrillat ion, 
stroke, pulmonary embolism and deep vein thrombosis. 
Several new oral Factor Xa and thrombin inhibitors have received approval for clinical use 
in anticoagulant therapy. These new oral anticoagulants or NOACs include Xarelto, Eliquis and 
Savaysa,(2) which are FXa active site inhibitors, and Pradaxa(3) which is a thrombin inhibitor. 
These drugs are a significant improvement over Coumadin but as use of these drugs expands, 
bleeding remains a concern,(4) particularly in the treatment of arterial thrombosis. 
Each of these drugs binds in the active site of a coagulation protease and is a competitive 
inhibitor of its target enzyme. Following classical Michaelis-Menten kinetics, as competitive 
inhibitor concentration increases, enzyme activity decreases until at saturating concentrations, 
activity approaches zero. Although prescribed drug levels are designed to achieve a safe and 
effective concentration, increased drug plasma levels can result from impaired renal clearance, 
drug-drug interactions, improper time between dosing and accidental over-dosing. These increases 
in drug plasma concentrations give rise to a potential bleeding diathesis. Alternative approaches 
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to anticoagulant therapy with truly novel starting points are needed to circumvent the bleeding 
liability of these active-site targeted agents. 
The prothrombinase (PTase) enzymatic complex, consisting of the enzyme factor Xa 
(FXa), a protein cofactor, factor Va (FVa), associated on the surface of negatively charged 
phospholipid membranes in the presence of divalent metal ions,(5,6) forms a critical junction of 
the blood coagulation cascade pathways.(7) This complex catalyzes the cleavage of prothrombin 
(PT) leading to the formation of thrombin and subsequent clot-formation.(8) FXa alone can slowly 
activate PT, but the rate of thrombin formation is enhanced by >105 by the presence of the cofactor, 
FVa and Ca2+ on phospholipid membranes in the PTase complex.(9,10) 
FXa consists of two chains– the light chain of 139 residues, and the heavy chain of 305 
residues that contains the catalytic active site and is connected via a disulfide (Cys132-Cys302) 
bridge to the light chain.(11) A wealth of structural data is available for this protein; over 150 
crystal structures of the protein or protein-ligand complexes have been deposited in the 
Brookhaven Protein Data Base (PDB).(12) Activated human FVa consists of a non-covalent 
calcium-dependent complex between the heavy chain (Hc: A1 (1–303)-A2 (317–656) domains) 
and the light chain (Lc: A3 (1546–1877)-C1 (1878–2036)-C2 (2037–2196) domains) in which the 
cofactor binding site is exposed for interaction with FXa.(13,14) Several studies have shown that 
both the Hc and Lc of FVa are involved in the binding of FXa, and also give some insights about 
FVa residues interacting with FXa.(15-19) In addition, some regions in the Hc of FXa have been 
suggested to be important for the interaction with FVa.(20-26) High-resolution crystal structures 
of FXa are available,(27) and homology models of FVa using the crystal structure of inactivated 
bovine FVa (FVai)(28) have also been built. Using these two structures, models of the FVa–FXa 
complex have been generated that are in agreement with available experimental data.(29)  
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The goal of this study is to target FXa within the PTase complex, but instead of seeking 
another active-site directed inhibitor, high-throughput virtual screening methods are used to 
identify compounds that are likely to bind to FXa and alter the interaction between FXa and FVa, 
and hence have the potential to down-modulate the PTase activity in an allosteric and non-
competitive manner.  
 
Materials and Methods 
FXa-FVa binding site 
The active site-inhibited human FXa structure, solved by X-ray crystallography (PDB 
code: 1XKA), was used as the starting structure.(27) It has a 2.3 Å resolution and no gaps in the 
structure. MD simulations in previous studies showed that the light chain, which is connected to a 
negatively charged phospholipid membrane in the PTase complex, and does not form any 
interactions with FVa, is highly flexible in aqueous solution and undergoes angstroms-wide 
fluctuations within a few nanoseconds of the MD.(30) To focus on the serine protease domain that 
interacts with FVa, this flexible part was removed and only the globular heavy chain was used in 
the MD calculations.  Homology models of FVa using the crystal structure of inactivated bovine 
FVa (FVai) have been built by other groups.(28) Using these models and the crystal structure of 
FXa, models of the FVa–FXa complex have been generated that are in agreement with available 
experimental data.(29) These models and the available experimental data were used to identify the 
regions of FXa that have been suggested to be important for the interaction with FVa. 
Figure 1A shows the FXa binding surface that is proposed to interact with FVa, based on 
the FVa–FXa complex models, consisting of twenty-eight residues. They form part of 3 helices-  
H1, H2 and H3 and one loop, L1, shown in Figure 1B. 
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Recently, the crystal structure of the FX:FV complex from the venom of Pseudonaja textilis 
has been solved.(31) The complex shows specific interactions between the structured A2 and A3 
domains of FV and FX. The highly flexible terminal region following the A2 domain forms non-
directional/non-specific ionic interactions and lacks a fixed binding mode, and only a small 
hydrophobic portion at the end of this region (IFADIFI) was well resolved. 
The FXa binding interface selected in the current study can be compared to the crystal 
structure of the FX:FV complex from P. textilis. Human FX and FV sequences show an identity 
of 50.5% and 53.5 % with the P. textilis sequences, respectively. Figures 1C shows the 
superposition of the human FXa crystal structure with the FX-FV complex from P. textilis (PDB 
code: 4BXS). The selected human FXa:FVa binding site consisting of 3 helices and 1 loop also 
forms the interface between FX:FV complex from P. textilis (Figure 1C).  The FXa/FVa contact 
region mapped on human FXa shown on Figure 1A is essentially reproducing the P. textitlis’s 
protein:protein interface.  
 
MD Simulations and Clustering 
The dynamics (MD) of the FXa heavy chain was characterized using molecular dynamics 
(MD) simulations. The active site ligand and the light chain were removed. One calcium ion known 
to be structurally important(32,33) was kept in the structure. The structure was protonated 
according to estimated pKa calculations using the Protonate-3D facility in MOE, version 2011,(34) 
with an ionic concentration of 0.1 mol/L in the Generalized Born (GB) electrostatics model. A 
periodic solvation cube of water molecules was created using the Solvate facility in MOE-2011. 
Seven negative chloride ions were added to neutralize the system, and the final system consists of 
22,516 atoms, with 6279 water molecules. The system was energy minimized to a gradient of 10-
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5 RMS kcal/mol/Å2 using the CHARMM-22 force field(35) and a 8Å-10Å nonbonded cutoff. 
NAMD2 input files were generated using the Dynamics facility in MOE-2011. MD simulat ions 
using the NAMD2 simulation engine(36) were performed using an integration time-step of 2 
fs/step, holding covalent bonds in water molecules rigid. A constant temperature of 300K was 
maintained throughout the simulation using Langevin dynamics. Particle Mesh Eswald (PME) was 
used for calculation of the electrostatic interactions with the periodic boundary conditions. 
Simulations were performed in the NVT ensemble. The MD simulation was run on the Univers ity 
of Tennessee High Performance Computing architecture (Newton). A 100 ps initial equilibra t ion 
was performed followed by a 300 ns production trajectory. The resulting trajectories were analyzed 
for convergence of temperature and RMSD using perl scripts for parsing data, Prody v1.2(37) and 
Gnuplot v4.6.  
Structures of the protein along the MD trajectory were generated every 50ps using Prody 
v1.2, i.e., generating a total of 6,000 structures. Nearest-neighbor RMSD clustering was used to 
cluster these structures with Maxcluster(38) using RMSD distance between the data point 
represented by each structure. Two structures were considered part of the same cluster if they were 
closer to each other than the cut-off threshold distance, i.e. if they were nearest-neighbors. The 
entire ensemble docking process flowchart is shown in Figure 2.  
 
Ligand and Receptor Preparation for Docking 
Virtual screening was performed using the program Autodock Vina(39) on 12  structures: 
11 structures obtained from the MD clustering described above, and the FXa crystal structure. The 
'clean drug-like' subset of the ZINC database(40) was used, consisting of ~11.1 million compounds 
without reactive functional groups, and that do not violate any of the Lipinski's criteria. The subset 
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of compounds used for virtual screening contained  244,493 compounds (referred as “Subset A” 
from here on) and covered 90% of the 'clean drug-like' compounds of ZINC database’s chemical 
diversity based on Tanimoto’s similarity coefficient.(41) These compounds were converted from 
the smile format to the PDB format using Babel v2.3.3(42) with the generate-3D option. The 
geometries of the ligands were optimized using the MMFF94 force field(43) in Babel. The 
compounds’ coordinates in PDB format were converted to PDBQT format using the Prepare 
Ligand scripts provided in ADT/MGL tools v1.5.4.(44) The FXa structures in PDB format from 
the clustered MD trajectory were also converted to PDBQT format directly in ADT tools. The 
configuration files for each FXa structure, including the docking grid box dimensions and the box 
center, used as input for docking in Autodock Vina, were created using ADT tools.   
The Subset A compounds were docked in the crystal structure and in the first 11 
representative structures from MD trajectory clustering, as indicated in Figure 2, allowing 
additional conformations of the ligand by sampling the rotatable bonds, and keeping the protein’s 
sidechains rigid. The docking was performed “agnostically,” i.e., binding could happen anywhere 
on the protein without imposing a particular binding site using Autodock Vina and an 
exhaustiveness value of 100 on the Newton cluster.  
 
Docking Analysis and Secondary Compound Selection 
Perl scripts were used to select the best-scoring binding mode reported in the AutoDock 
Vina output for each ligand and to parse these binding modes in order to identify ligands that bind 
in the regions of FXa involved in FVa interactions (steps III in Figure 2). 
The top 80 ranked compounds in the crystal structure and top 40 ranked compounds in 
each of the other 11 MD snapshots (representing a total of 520 compounds) were identified from 
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the docking calculations.  ZincPharmer,(45) a pharmacophore search tool for screening the Zinc 
database, was used to identify an additional 42,309 compounds in the ZINC database that are 
chemically similar to the docking hits but with larger molecular weights (step IV in Figure 2). 
These compounds were parsed to keep only the drug-like compounds with properties as defined 
in the Zinc database, i.e., 150 ≤ mol wt ≤ 500, xlogp ≤5, -5 ≤ net charge ≤ 5, rotatable bonds ≤ 8, 
polar surface area < 150 Å2, no. of H donors ≤ 5, no. of H acceptors ≤ 10, -400 ≤ polar desolvation 
energy ≤ 1 kcal/mol, -100 ≤ apolar desolvation energy ≤ 40 kcal/mol, and also to remove any 
duplicates, giving a total of 36,635 compounds (referred as 'Subset B' from here on), correspond ing 
to step V in Figure 2. These compounds were again docked in the 12 structures using Autodock 
Vina on the UTK’s Newton High Performance cluster with the same configuration settings as 
described above. Perl scripts were again used to parse the docking results for compounds that bind 
in the regions of FXa involved in FVa interactions.  
 
Analysis of Compound Lists 
The results from docking of Subset A (step II in Figure 2) and Subset B (step VI in Figure 
2), indicated that compounds can bind in different sub-binding sites at the FXa-FVa interface, in 
different protein MD snapshots. Based on the clustering of the binding loci for these compounds, 
the FXa-FVa interface was divided into ten sub-binding sites.  
The computational hits were analyzed using two main criteria (in addition to their predicted 
binding energies): the number of MD snapshots to which they were predicted to bind, and the 
number of sites in the protein where a compound is predicted to bind. This allows the identifica t ion 
of compounds that bind to a large number of target structural variations and binding site(s). A 
value named “snapshot count” was calculated using Perl scripts that gives the total number of 
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snapshots in which a given compound binds to the FXa-FVa interface. Compounds found to bind 
to most snapshots were checked for the different sub-binding sites (on FXa-FVa interface), 
yielding another value named “binding-site score” that gives the number of sub-binding sites that 
a given compound is docked.  
Two lists of compounds were generated for experimental validations: first, a list that 
contained 288 compounds consisting of the strongest binders in the crystal structure and the 11 
snapshots, as predicted by Vina docking scores (shown in step VIIIa of Figure 2). Second, a list 
was generated that contains 247 compounds with “snapshot count” scores of three and above (i.e., 
including compounds that successfully bind to three or more different protein conformations) and 
“binding-site scores” of one or two (i.e. removing promiscuous compounds that bind in many sites 
in different snapshots), shown in step VIIIb of Figure 2. The first list thus contains compounds that 
are predicted to bind with the highest binding affinities at the FXa-FVa interface, and the second 
list contains the compounds that can bind to different protein conformations but at the same time 
are selective for particular binding sites at the interface.  
Visual inspection was performed on the compounds in the two lists to insure their 
commercial availability and affordable cost, and to identify and remove compounds with reactive 
functional groups (e.g. aldehydes and alkyl bromides), excessive hydrophobicity (LogP >5), a lack 
of functionalization (e.g. polyaromatics with few or no functional groups) or an excess of 
functionalization, the latter two of which would render synthetic analoging difficult for any follow 
up structure-activity relationship (SAR) studies. The compounds ordered for experimental testing 
were selected to sample different sub-binding sites at the interface as predicted by the docking, be 
of affordable cost and presenting desirable chemical features.  
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Experimental Validation 
Initial screening of these compounds for potential FXa inhibitors was performed using a 
prothrombinase assay as described by Nesheim et al.(9) FXa, FVa, prothrombin and thrombin were 
purchased from Hematologic Technologies. The thrombin and FXa substrates S-2238 and S-2222, 
respectively, were obtained from diaPharma. Apixaban was purchased from Selleckchem. PTase 
activity measurements were initiated by the addition of prothrombin to the reaction mixture, and 
the rate of thrombin generation was determined by measuring thrombin activity towards the 
chromogenic substrate S-2238. Replicate samples were analyzed and the rates were corrected for 
the very low rate of hydrolysis of S-2238 by FXa. FXa activity was measured using the substrate 
S-2222. Assay data was analyzed using GraphPad Prism 5.0f to obtain kinetic parameters. 
Structural analogs of the identified hits were searched from the list of all the compounds 
used for docking, including Subsets A and B, using Tanimoto coefficient and the MACCS 
structural keys fingerprints(46) in MOE-2011. Similar compounds not present in this list were also 
identified directly from the ZINC database using substructure searching. Further filters described 
above were also applied on these compounds to order a second set of compounds. All compounds 
were dissolved in anhydrous spectroscopic grade DMSO at 10 mM and were stored in sealed vials 
at -20°C. Compounds were diluted in the assay to final concentrations of 5 to 100 μM. The final 
DMSO concentration in the assay was kept constant at 1%. 
 
Binding Sites Analysis  
The initial FXa inhibitors identified by PTase activity assays (and given in results) were 
re-docked in the binding sites identified with Vina using MOE-2011 with the CHARMM27 Force-
field, allowing protein sidechain flexibility. Additional conformations of the ligand were allowed 
 137 
by sampling the rotatable bonds. Binding site residues side-chains were allowed to move away 
from their original location using a tethering weight of 0.1. The GBVI/WSA dG scoring 
function(47) was used for scoring different poses of the docked ligand. The top ranked binding 
poses were energy-minimized and the compounds’ predicted binding free energies were calculated 
using a MM/GBVI-adapted protocol.(48) 
 
Results 
MD Simulations and Clustering  
The FXa heavy chain structure including the FXa-FVa binding interface residues were 
found to sample different conformations in the MD snapshots as shown in Figure 3A. Figure 3B 
shows the RMSD plot for the protein backbone over the time course of the trajectory. Generally, 
MD simulations are considered stable when the backbone RMSD is in the low angstrom area.(30) 
However, in the case of FXa, higher RMSD values ranging between 2 and 7 Å have been 
reported.(49-51) Based on the RMSD plot in Figure 3B, the FXa structure converges after the first 
100 ns of the trajectory. 
Nearest-neighbor RMSD clustering was used to divide the trajectory into 15 clusters as 
described in Methods. Figure 3C shows the superposition of these structures, also represented on 
the RMSD plot (Figure 3B) over the time course of the trajectory.  
 
Docking in AutoDock Vina 
The docking of compound Subset A in 12 FXa structures (crystal structure and 11 
representative structures from 15 clusters) represented a total of ~2.9 million docking calculat ions 
(step II in Figure 2). After selecting the best scoring poses of docked ligands as predicted by 
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AutoDock Vina and parsing these for the selected FXa-FVa binding sites, it was found that in the 
crystal structure most of the compounds (99.8%) bind to sites outside of the FXa-FVa interface, 
mostly in the protein active site, and only around 0.2% of compounds screened (532 compounds 
in the case of crystal structure) bind to FXa within the FXa-FVa interface. As the MD snapshots 
sample larger conformational space, more compounds bind at this interface compared to the 
number that bind to the crystal structure. Docking of Subset B compounds in the 12 structures 
represented another ~0.45 million docking calculations (step VI in Figure 2). In the case of crystal 
structure, only 177 of these compounds (0.5%) bind to FXa within the FXa-FVa interface, and the 
higher hit rate compared to Subset A could be expected due to the larger MW’s of Subset B 
compounds. Figure 4A shows the comparison between a compound from Subset A and one from 
Subset B binding in the FXa-FVa interface in the crystal structure (both compounds were later 
identified as inhibitors). As one would expect, larger compounds are found to bind to larger regions 
on the FXa surface, and also often (although not in all cases) exhibit better binding (docking) 
scores than smaller compounds. 
 
Docking Analysis and Compound Lists 
In the crystal structure the compounds that bind in the FXa-FVa interface were found to 
bind essentially in four regions represented by four grooves, shown in Figure 4B. Taking the 
docking results from all snapshots together, the interface was divided into ten sub-binding sites, 
as shown in Figure 4C and Table 1, with sub-binding sites 1, 4, 5, 6 and 9 corresponding to groove-
A, groove-B, groove-C, groove-D and groove-E in the crystal structure, respectively. Other 
binding sites were not observed in the crystal structure but only in MD snapshots. The ten binding 
subsites are thus defined by the localization of compounds observed in the docking studies as 
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opposed to the topological features of the protein surface as observed in the crystal structure. It 
was found that compounds with top snapshot count scores were concentrated in sub-binding sites 
9 (52%), 7 (27%) and 10 (4%), respectively. Compounds with low binding-site scores of 1 and 2 
mostly bind to binding site 9 as well. This site is relatively large and present at the center of the 
binding interface.  
The strongest binders as predicted by Vina docking scores were also concentrated in sub-
binding site 9 (43%), 7 (38%) and 10 (22%). These compounds are weighted heavily from Subset 
B (~91%), compounds that arose from the pharmacophore based search around the best-ranked 
compounds from Subset A, and represent an overall higher molecular weight. 
 
Experimental Validation 
After employing further filters to the compounds in the two lists based on compounds' 
availability, cost, chemical similarity, and presence of reactive functional groups, compounds were 
ordered for experimental validation, shown in step IX of Figure 2. The majority of these selected 
compounds were predicted to bind in sites 9 and 7, with some representation of the remaining 
binding sites. Compounds were screened for solubility in the assay buffer (about half were soluble 
at 100 μM) and for their effect on PTase and FXa enzyme activity. Initial screening of these 
compounds at 100 μM concentration was performed in a PTase activity assay measuring inhibit ion 
of the rate of generation of active thrombin using the thrombin specific chromogenic substrate, S-
2238.  Further screening of these compounds with inhibitory activity was performed as a function 
of inhibitor concentration from about 5 μM to 100 μM. PTase activity assays identified 16 
compounds as inhibitors for the PTase activity, out of the initial compounds suggested from the in 
silico calculations. Eight of these 16 compounds were not computationally predicted to bind well 
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in the crystal structure but were predicted to bind well in one or more of the MD snapshots. These 
inhibitors would not have been identified if the docking calculations had been made using only the 
crystal structure. Ten more inhibitors were identified from a screen of structural analogs (step Xa 
and Xb in Figure 2) of those compounds that were obtained for initial screening. A total of 26 
inhibitors were identified. 
These compounds inhibit PTase activation of thrombin from prothrombin in the presence 
of FVa, but at a concentration of 100 µM, these compounds do not inhibit the activity of FXa 
towards the chromogenic substrate S-2222 indicating that they do not bind to the active site of the 
FXa molecule. Similarly, the compounds do not inhibit thrombin activity towards its chromogenic 
substrate, S-2238. The compounds thus appear to be specific inhibitors of the PTase complex, and 
inhibition is dependent upon the interaction between FXa and FVa.  
When these 26 compounds were assayed as a function of inhibitor concentration, 10 
compounds exhibited incomplete or partial inhibition of PTase activity even at high concentrations 
of inhibitor. Figure 5A, which shows percent inhibition as a function of [I]/Ki, contrasts the effects 
of five of these partial inhibitors on PTase activity with the anticoagulant apixaban, which is an 
active site competitive inhibitor of FXa. The characteristic feature of these novel inhibitors is that 
they achieve or approach plateau levels of inhibition as the concentration of inhibitor is increased. 
Maximal inhibition, calculated from the inhibition curves, is 100% for apixaban and 25%, 40%, 
80% and 90% for SBC-160,029, SBC-160,119, SBC-160,042 and SBC-160,109/SBC-160,012, 
respectively.  
SBC-160,029 was identified by the computational screen as a member of a substituted 
tetrazole series and binds to FXa in four snapshots, including the crystal structure. SBC-160,029 
docked exclusively in Site 9. SBC-160,029 inhibits PTase activity to about 25% with a Ki of 15 
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μM. Two analogs (Table 2), SBC-160,124 and SBC-160,125, exhibit similar inhibitory activity 
and comparable Ki values. 
Compounds SBC-160,012 and SBC-160,042 were also identified as site 9 binders; both 
compounds also dock into site 7 in other MD snapshots. SBC-160,012 docks in site 9 in the crystal 
structure and two other snapshots, but docks to site 7 in snapshot 10. SBC-160,042 does not dock 
in the crystal structure, but docks in site 9 in one snapshot and in site 7 in another (Table 3). With 
the exception of SBC-160,042 (Ki = 30 uM) these inhibitors have similar affinity for FXa with Ki 
values of 10 ± 5 μM, but the maximal inhibition for each compound varies from about 25% (029) 
to about 95% (012). Comparing the series of site 9 inhibitors indicated that maximal inhibit ion 
increased with increasing size of the inhibitor. Figure 5B shows the change in maximum PTase 
inhibition with the molecular weights of the compounds. It can be seen that larger compounds 
inhibit PTase activity to a greater extent. SBC-160,109, which is a tight binding analog of SBC-
160,042 with higher molecular weight, shows greater inhibition, contrasted with SBC-160,119, 
which has lower molecular weight and lower inhibition than SBC-160,042. Interestingly, SBC-
160,012, which has a relatively small molecular weight, is a clear outlier from this trend suggesting 
a complex inhibition mechanism. 
These hits comprise three families of inhibitors as represented by SBC-160,029, SBC-
160,012 and SBC-160,042, respectively. SBC-160,099, SBC-160,109, SBC-160,112 and SBC-
160,119 were selected from a panel of structural analogs of SBC-160,042. 
In summary, from around 3.4 million docking calculations, the computational results 
yielded 535 compounds that could potentially bind at the FXa-FVa interaction region. Twenty six 
hits were identified, with 10 of them represented by three families of inhibitors exhibiting partial 
inhibition of PTase activity in which the extent of inhibition reaches a maximal value so that further 
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increases in inhibitor concentration do not further inhibit PTase enzyme activity. We refer to this 
as self-limiting inhibition.  Four of these self-limiting inhibitors originated directly from the 
docking calculations.  
 
Sub-binding Sites Analysis  
Table 3 shows three families of inhibitors, represented by parent compounds SBC-160,012, 
SBC-160,042 and SBC-160,029. These compounds were identified as non-active site or allosteric 
inhibitors by PTase and FXa activity assays. Compound SBC-160,029 binds in only site 9, whereas 
SBC-160,012 and SBC-160,042 are able to potentially bind in either site 9 or site 7 in separate 
snapshots. Table 4 lists the difference in predicted binding energies calculated using the 
MM/GBVI protocol in MOE for the two compounds binding in site 7 and in site 9 in snapshot 10. 
The results indicate that compound SBC-160,012 is predicted to bind more strongly in binding site 
7 than in binding site 9. Compound SBC-160,042, however, is predicted to bind more strongly in 
binding site 9.  
Table 5 gives the cluster population from which the representative snapshots (centroid 
structures) were selected. Among the snapshots to which these compounds bind, site 9 was 
identified in snapshots 2 and 4, and these show relatively high cluster populations. Binding site 7, 
however, was identified only in snapshot 10 that represents a cluster of structures that was found 
only 0.5% of the time in the molecular dynamics trajectory; i.e. snapshot 10 represents structures 
rarely sampled. This makes binding in site 7 for compound SBC-160,012 a rare but possible 
binding pose, which is nonetheless quite significant in terms of the strength of the interaction (G 
-3.72).   
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Site 9 was observed in the crystal structure, but its shape and structure change significantly 
during the MD simulation. Figure 6A shows a compound identified initially as an inhibitor that 
binds to site 9 only in the later snapshots and not in the crystal structure. Sub-binding site 10 was 
not seen in the crystal structure and became apparent in 3 of the 11 snapshots from the MD 
trajectory. Figure 6B shows one of the compounds initially found as a non-active site binder 
docked in snapshot 7, and how it is not possible for it to bind to the crystal structure. 
 
Discussion 
Results from clustering the MD trajectory indicate that the regions of FXa that interact with 
FVa sample a relatively large accessible conformational space, as seen in Figures 3A and C, and 
that ligands are predicted to interact with FXa in a way that would not necessarily be observed 
from an analysis that focused solely on the starting crystal structure. These structural variations 
shown in the MD translated into a diverse set of compounds that potentially bind to FXa’s 
conformations. 
Larger compounds are found to bind to larger sites on the FXa surface, with binding 
(docking) scores that predict tighter binding compared to smaller compounds in the Subset A, 
which will likely prove advantageous in modulating the FXa-FVa protein-protein interaction. 
Figure 5B supports the hypothesis that larger compounds are better able to alter the FXa-FVa 
interaction. Compound 12, the outlier in Figure 5B, which is predicted to bind preferentially to 
binding site 7 according to free-energy calculations, may follow a more complex inhibit ion 
mechanism. 
Compounds with low binding site scores of 1 and 2 mostly bind to sub-binding site 9, a 
relatively large area at the center of the FVa binding interface. This site is particularly important 
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for inhibiting the FXa-FVa interaction, as compounds that bind at this site interact with residues 
from all three helices of interest (H1, H2 and H3). This site was observed in the crystal structure, 
but its shape and structure change significantly during the MD simulation, as shown Figure 6A. 
Eleven of the 26 non-active site inhibitors identified by PTase activity assays (including 10 
structural analogs which were not docked to generate binding site data) are predicted to bind to 
site 9. This includes 3 out of the 10 compounds (comprising 6 of the 10 analogs) that achieve self-
limiting inhibition of PTase activity.  
Among the 10 self-limiting inhibitors, only two compounds were observed to bind to the 
crystal structure. Sub-binding site 10 was not seen in the crystal structure and became apparent in 
3 of the 11 snapshots from the MD trajectory, where two loops that are close to each other in the 
crystal structure open up, as shown in Figure 6B. SBC-160,064 is a non-active site-inhibitor, 
inhibiting PTase activity by about 20% at 100 μM, and is predicted to bind in this site but would 
not have been identified from the crystal structure searches alone.  
Tables 3 and 5 indicate that, while compounds appear to bind in site 9 (snapshots 2, 4 5 
and 9) an order of magnitude more often than in site 7 (snapshot 10), the predicted binding affinity 
of compound SBC-160,012 is stronger in site 7 by 3.72 kcal/mol. Hence, this compound’s 
predicted binding site is difficult to assess: site 9 is more often accessible but binding in site 7 is 
more stable. It is theoretically possible that the compound may bind at both sites and possibly 
simultaneously. Inversely, binding of compound SBC-160,042 is predicted to happen most likely 
in binding site 9 since the predicted binding free energy of this compound is better in site 9 than 
in site 7 by 2.38 kcal/mol.  
The comparison of the human structure and the crystal structure of the prothrombinase 
complex from the venom of P. textilis(31) suggests that the binding sites investigated here are 
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relevant. Figures 7A and B show the superposition of human FXa (crystal structure) bound with a 
site-9 inhibitor in its predicted binding mode, with the FX-FV complex from P. textilis. Site-9 
inhibitors discovered from the computational approach bind directly at the interface of FXa and 
the A2/A3 domains of FV, possibly interfering with the specific interactions between these 
proteins. Figures 7C and D show the superposition of human FXa (snapshot 10 from MD 
simulation) containing an inhibitor predicted to bind in site-7, with the P. textilis FX-FV complex. 
In this snapshot the flexible loop L1 folds to form site-7, which is not seen in the crystal structure 
of human or P. textilis FXa. As seen in this MD snapshot, binding in site-7 can interfere with the 
interactions between human FXa and the small hydrophobic portion of the terminal region in FV.  
Compounds binding to other sites on the human FXa-FVa interface did not inhibit the 
prothrombinase activity possibly because of the non-specific nature of ionic interactions between 
FX and the flexible terminal region following the A2 domain of FV in the P. textilis crystal 
structure. This flexible region of FV may sample alternate binding modes that can overcome the 
interference of the inhibitors binding to FXa at these sites. 
The initial aim of this study to identify compounds that reduce the PTase activity has been 
met as shown in Figure 5A. In future virtual screening studies, additional compounds can be 
identified for experimental validation. In addition, lead optimization can be aided by the chemical 
structures and binding poses of positive hits predicted to bind at both site 7 and site 9. Library 
design can be based on compound modifications guided by pharmacophore features associated 
with active compounds, while at the same time avoiding those features associated with inactive 
compounds (e.g., volume exclusion). It should also be possible to differentiate between binding in 
site 7 and site 9 from the experimental testing of compounds originating from the pharmacophore 
features of the active compounds binding at these two sites, as well as directed mutagenesis studies 
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that would affect the predicted potential binding modes identified computationally. These 
compounds will be used to identify new hits and to develop structure-activity relationships (SAR) 
in order to identify more potent and selective lead compounds against PTase. 
 
Conclusion 
This study used an ensemble docking approach to identify structural variations of FXa 
using MD simulations, and targeted these conformations with compounds that specifically bind to 
the FXa-FVa interface to modulate the PTase activity in an allosteric and non-active site dependent 
manner. In contrast to competitive active site inhibitors, which completely inhibit enzyme activity 
at saturating inhibitor concentrations, these allosteric PTase inhibitors exhibit a plateau in 
inhibition referred to as 'self-limiting inhibition’. PTase activity assays identified a total of 26 
compounds as inhibitors. Only 8 of these compounds were predicted to dock in the crystal 
structure. From these non-active site inhibitors, 10 compounds, 4 of which were identified by 
initial screening and 6 that were structural analogs, achieved self-limiting inhibition of PTase. 
Only two of these compounds bind to the crystal structure, and two compounds and their analogs 
would not have been identified if the virtual screen had used only this one structure. 
This study exemplifies a successful MD simulation and high-throughput virtual screening 
approach to drug discovery targeting a protein-protein complex. Amaro et al. showed the 
importance of employing molecular dynamics to account for protein flexibility in the discovery of 
new molecules for African sleeping sickness.(52) Here we apply a similar ensemble docking 
approach, but use a larger compound database covering a larger chemical space, with around 3.4 
million docking calculations completed in total. In future studies the same approach can be 
extended to even larger compound databases covering millions of compounds and targeting 
 147 
multiple protein targets, using massive high-throughput screenings on supercomputers like 
TITAN.(53,54) This can increase dramatically the number and diversity of compounds that can be 
identified, while at the same time taking into account the inherent flexibility and the dynamic 
nature of macromolecules and their complexes under physiological conditions.  
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Table 3.1. Ten sub-binding sites identified at the FXa:FVa interface and the corresponding FXa 
residues in these sites that are proposed to interact with FVa (Figure 3.1A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sub-binding site Residues  
1 Arg-125, Asp-126, Trp-127 
2 Val-231, Leu-235 
3 Val-231, Ile-238 
4 Arg-125, Asp-126, Val-231, Thr-232, 
Ala-233, Phe-234, Leu-235, Lys-236, 
Trp-237, Ile-238, Asp-239, Arg-240 
5 Glu-129, Thr-232, Ala-233, Phe-234, 
Leu-235, Lys-236, Trp-237, Ile-238 
6 Ser-241, Met-242, Lys-243, Arg-93, Phe-
94 
7 Arg-93, Phe-94, Thr-95, Lys-96 
8 Arg-93, Phe-94, Thr-95, Lys-96 
9 Arg-125, Asp-126, Trp-127, Ala-128, 
Glu-129, Asp-164, Arg-165, Asn-166, 
Ser-167, Cys-168, Lys-169, Leu-170, 
Val-231, Thr-232, Ala-233 
10 Asp-164, Arg-165, Asn-166, Ser-167, 
Cys-168, Lys-169, Leu-170 
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Table 3.2. Nine self-limiting inhibitors identified by PTase activity assays. The compounds 
without “Binding Sites” values are the structural analogs of compounds obtained for init ia l 
screening. Max % inhibition and Ki, were obtained by fitting activity inhibition as a function of 
inhibitor concentration. 
 
SBC  ID 
Inhibition 
@ 100 uM 
Max % 
inhibition 
Ki, μM 
Binding 
Sites 
Binds 
Xtal 
Structure 
SBC-160,010 65-70 80±10 25 7/8* No 
SBC-160,012 85-90 95±5 10 9,9,9,7 Yes 
SBC-160,029 15-30 25±5 15 9,9,9,9 Yes 
SBC-160,042 60-70 85±10 30 9,7 No 
SBC-160,109 85-95 90±5 5 - - 
SBC-160,114 20-25 25±5 10 - - 
SBC-160,119 35-40 40±5 10 - - 
SBC-160,124 15-20 23±5 5 - - 
SBC-160,125 20-25 25±5 20 - - 
      
*Binding across both sites 7 and 8 
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Table 3.3. Compounds experimentally tested to be active. Binding snapshot 1 represents the 
crystal structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Structure Molecular 
Weight 
Binding 
Snapshots  
Binding 
sites  
 
 
 
 
SBC-160,012 
 
 
 
 
 
276 
 
 
 
 
1,2,4,10 
 
 
 
 
9,9,9,7 
 
 
 
 
SBC-160,029 
 
 
 
 
 
236 
 
 
 
 
1,2,5,9 
 
 
 
 
9,9,9,9 
 
 
 
 
SBC-160,042 
 
 
 
 
 
388 
 
 
 
 
4,10 
 
 
 
 
9,7 
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Table 3.4. Differences in binding free energy for selected compounds in binding site 9 and binding 
site 7 in snapshot 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound G (G  site 7 – G site 9) 
Kcal/mol 
SBC-160,012 -3.72 
SBC-160,042 +2.38 
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Table 3.5. Cluster population for the snapshots that compounds 012, 029 and 042 bind to. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Snapshot 
number 
Cluster population (in % of MD 
structures) 
2 10.7 
4 4 
5 1.3 
9 2.3 
10 0.5 
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Figure 3.1. FXa-FVa binding site. (A) Human FXa residues proposed to interact with human 
FVa, based on the FVa–FXa complex models and the available experimental data. Binding site 
residues 93-96, 125-129, 164-170, 231-244 shown in green.  (B) Residues (green) form part of 3 
helices- H1, H2 and H3 and a loop, L1. (C) Superposition of human FXa with the FX-FV complex 
from P. textilis. Only superposed human FXa (red) and P. textilis FV (blue) are shown and P. 
textilis FX structure is not shown for clarity. Binding interface (green) in human FXa proposed to 
interact with human FVa. 
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Figure 3.2. Flowchart showing the Ensemble docking process. I. (a) 300 ns MD simula t ion 
carried out followed by (b) Nearest-neighbor RMSD clustering, generating 15 snapshots. II. 244K 
compounds docked, covering 90% of 11.1 million “clean drug-like” subset from the Zinc database. 
III. Parsed for compounds that bind to FXa:FVa interface in the crystal structure or at least one of 
the 11 snapshots. Only 532 out of 244,493 docked compounds bind at this interface in the crystal 
structure. IV. (a) Top 80 compounds in the crystal structure + top 40 compounds in each of 11 
snapshots selected (520 total) for (b) pharmacophore search with ZincPharmer for larger 
compounds (MW 280-600 amu’s), against purchasable Zinc database compounds. V. Compounds 
parsed for drug-like properties and redundant compounds removed. VI. 37,000 larger compounds 
docked in 11 snapshots + crystal structure. VII. Parsed again for compounds that bind to FXa:FVa 
interface in the crystal structure or at least one of the 11 snapshots. Only 177 out of 36,635 docked 
larger compounds bind at this interface in the crystal structure. VIII. (a) Top 50 compounds in 
crystal structure + top 30 compounds from each of 11 snapshots based on docking scores selected: 
288 compounds (after removing redundancy), from which 44 bind to the crystal structure and 
others bind to MD snapshots. (b) 247 compounds selected that bind to most number of snapshots 
and only 1 or 2 different binding sites on FXa-FVa interface. Out of these 79 bind to the crystal 
structure and others bind to MD snapshots. IX. Compound selection based on compounds' 
availability, cost, chemical diversity, and lack of reactive functional groups. X. (a) Analog 
generation based on initial positive hits. (b) Experimental validation of these analogs. 
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Figure 3.3. MD Simulations and Clustering. (A) Superposition of 3 FXa structures at different 
times in the MD trajectory. Starting crystal structure shown in green, structure at 150 ns in blue 
and structure at 300 ns in orange, with binding site residues shown as stick-ball representation. (B) 
RMSD plot over the time course of the trajectory. (C) Superposition of representative non-
redundant structures from 15 clusters with binding site residues shown in white. Structures in (C) 
represented on the RMSD plot (B) as black dots. 
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Figure 3.4. Docking analysis. (A) Smaller original compound from the Subset A in blue and 
larger similar compound from the Subset B in brown binding in the FXa-Va interface in the crystal 
structure. The exposed regions are shown as red on the molecular surface, hydrophobic regions in 
green and polar regions in magenta. Larger compounds cover more binding surface. (B) In crystal 
structure compounds bind in four regions: grooves A, B, C, D and E. (C) Ten binding sites 
considered taking all 12 structures into account.  
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Figure 3.5. PT inhibition. (A) Effect of the identified inhibitors on PT activity based on activity 
measurements, presented as % inhibition vs. [I]/Ki. (B) Plot of the maximum inhibition vs. the 
molecular weights of identified PTase inhibitors and corresponding analogs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 3.6. Structural variations with MD. Superposition of loop backbones in FXa-FVa 
interacting region. Yellow: FXa crystal structure. Blue: snapshots from the MD trajectory. (A) 
Inhibitor (cyan) binds to sub-binding site 9 in snapshot 3 where the Helix 3 (H3) is pushed out, 
and not in the crystal structure. (B) Non-active site binder (cyan) binds to sub-binding site 10 in 
snapshot 7 where two loops move apart, opening the binding site. These loops occlude the binding 
site in the crystal structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
H3 
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Figure 3.7. Site 9 and 7 in FX-FV complex. (A) Superposition of human FXa (crystal structure) 
bound with a site-9 inhibitor, with the FX-FV complex from P. textilis. Only superposed human 
FXa and P. textilis FV are shown and P. textilis FX structure is not shown for clarity. Red: human 
FXa structure. Cyan: A2 domain from P. textilis FV. Green: A3 domain from P. textilis FV. Purple: 
Flexible terminal region in FV. Site-9 inhibitor binds directly at the interface of FXa and A2/A3 
domains of FV. (B) 90 degree rotation of (A). (C) Superposition of human FXa (snapshot 10 from 
MD simulation) bound with site-7 inhibitor, with the FX-FV complex. Hydrophobic portion of 
terminal region shown in stick conformation. (D) 90 degree rotation of (C).  
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Chapter 4  
ELUCIDATION OF THE PROTEIN-PROTEIN 
BINDING/DYNAMICS OF ELECTRON 
TRANSPORT PROTEINS WITH 
CYANOBACTERIAL PHOTOSYSTEM I 
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Abstract 
The Luminal domain (PsaA, PsaB, and PsaF) of photosystem I (PSI) in Cyanobacteria 
accepts electrons from Cytochrome c6. After a series of electron transfer steps, the stromal domain 
(PsaC, PsaD, and PsaE) transfers these electrons and reduces the transiently bound ferredoxin (Fd) 
or flavodoxin. Experimental structures exist for all of these protein partners individually, but no 
experimental structure of the PSI/Cytc6 and PSI/Fd complexes is presently available. Molecular 
models of Cytc6 docked on the lumen side and Fd docked onto the stromal domain of the 
cyanobacterial PSI site are constructed here utilizing X-ray and NMR structures of PSI, Cytc6 and 
Fd. Predictions of potential protein-protein interaction regions are based on previous experimenta l 
site-directed mutagenesis and cross-linking studies to guide rigid body docking calculations of 
these proteins. Agnostic docking without any constraints are also carried out, validating the PSI/Fd 
results, and providing an alternate binding mode for the PSI/Cytc6 complex. The results are 
complemented by the calculations of coevolving residues between the interacting partners on the 
two domains of PSI. These results further validate the complex models and provide a 
comprehensive picture of the binding and interactions between the PSI and the electron-transport 
proteins. 
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Introduction 
The process of photosynthesis converts light energy into chemical energy through two 
large, multi-subunit proteins bound to the thylakoid membranes in the chloroplasts of 
cyanobacteria, algae and plants. These large, multi-subunit proteins are referred to as Photosystem 
II (PSII) and Photosystem I (PSI). Upon photo-excitation, PSII extracts electrons from water, and 
transfers them to the b6/f complex and ultimately to PSI using soluble electron transfer proteins 
such as Cytc6 or plastocyanin (PC). PSI then undergoes a second photo-excitation, which induces 
a cascade of electron transfer steps through several redox cofactors within the protein, ending up 
at one of two terminal electron acceptors, the 4Fe-4S centers in the PsaC subunit. Electrons are 
then transferred from these 4Fe-4S centers to the 2Fe-2S center of ferredoxin (Fd) (1,2) or the 
flavin mononucleotide (FMN) cofactor of flavodoxin under iron-deficient conditions (3,4). The 
reduced Fd transfers two electrons to the ferredoxin-NADP oxidoreductase (FNR) to produce 
NADPH, which functions as a reducing agent in Calvin Cycle reactions as well as several other 
metabolic processes (5). Understanding the binding and affinity of Fd and Cytc6 with PSI is a key 
element of the structure/function relationship of the electron transfer mechanisms during the 
process of photosynthesis. 
The purpose of this study is to examine the atomic-level intermolecular interactions at the 
protein-protein interface in cyanobacterial photosynthetic proteins using advanced computationa l 
methods. Using the NMR structures of cyanobacterial Fd (6,7) and Cytc6 (8), and X-ray crystal 
structures of cyanobacterial PSI (9), molecular models of Fd docked onto the stromal domain and 
Cytc6 docked on the luminal domain of the cyanobacterial PSI are constructed. Docking models 
of PSI-Fd have recently been published by Cashman et al (10). The newly generated models are 
compared with these previously published models. Docking studies were guided by predictions of 
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protein-protein interaction regions from experimental site-directed mutagenesis (11,12) and cross-
linking (13,14) studies. Several plausible docked configurations are ranked based on the 
predictions of the coevolving residues between the interacting partners, forming the basis of the 
computational model prediction presented here. 
 
Materials and Methods 
Structure preparation 
Protein structures from T. elongatus, a thermophilic cyanobacterium, were used to model 
the interaction sites between the X-ray crystal structure of PSI and the NMR structures of Fd and 
Cytc6 (6-9). The structural files were downloaded from the PDB (15) using the PDB accession 
coordinates 1JB0 for photosystem I, 2CJN for Fd and 1C6S for Cytc6. In the case of PSI-Fd 
models, using MOE, v. 2012 (16) the PsaC, PsaD, and PsaE chains were extracted from the PDB 
file, and hydrogen atoms were added to the structure according to standard residue protonation. 
Similarly in the case of PSI-Cytc6 models, the PsaA, PsaB, and PsaF chains were extracted from 
the PDB file and hydrogen atoms were added. The remainder of the system was omitted, as it is 
not involved in interacting with Fd or Cytc6.  
 
PSI-Fd and PSI-Cytc6 binding sites 
To identify potential protein–protein interaction sites between the stromal domain of PSI 
(PsaC, PsaD, and PsaE) and Fd, the residues that have been experimentally determined on the basis 
of site-directed mutagenesis, cross-linking and other studies, to be involved in interactions with 
both systems (11,12,17,18) were used (Ile-11, Thr-14, Gln-15, Lys-34, Gly-36, Val-48, Lys-51, 
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Arg-52 from PsaC, His-95, Asp-98, Glu-103, Lys-104, Lys-107, Arg-109 from PsaD and Arg-39 
from PsaE).  
In the case of interactions between the Luminal domain of PSI (PsaA, PsaB, and PsaF) and 
Cytc6, the stretch of charged residues in Cytc6 shown to be involved in interactions with the 
Lumen side of PSI through mutagenesis studies (data unpublished) were used (Gly-63, Arg-64, 
Leu-65, Thr-66, Asp-67, Glu-68 and Gln-69). The stretch of residues from the multiple sequence 
alignment of PsaF domain in different species and containing the basic residues possibly involved 
in interaction with the corresponding acidic residues in Cytc6 (data unpublished) were also used 
(Ser-11, Pro-12, Ala-13, Phe-14, Gln-15, Lys-16, Arg-17, Ala-18, Ala-19, Ala-20, Ala-21, Val-
22, Asn-23, Thr-24, Thr-25). In addition, explicit repulsions were added between Cytc6 and the 
residues in PsaA, PsaB and PsaF present on the stromal side or interacting with the surrounding 
membrane regions. 
Agnostic docking, without using any constraints in the docking protocol, was done for 
comparison and to further validate the results generated using the residue filters for both PSI-Fd 
and PSI-Cytc6 models. In the case of PSI-Cytc6 models, explicit repulsions were retained to obtain 
a realistic set of results. 
 
Rigid-body docking  
Fast-fourier transform (FTT) based rigid-body docking program, Cluspro (19-21), was 
used for generating docking models between PSI and Fd and between PSI and Cytc6. The working 
of Cluspro is described as follow- Cluspro treats one of the proteins as the receptor (PSI in this 
case) and the other as the ligand (Fd or Cytc6). The translation and rotation of ligand with respect 
to the receptor is carried out on a grid, sampling around 109 positions of the ligand relative to the 
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receptor. Translation with the best score from each rotation is selected, using pairwise interaction 
potential scoring function based on attractive and repulsive contributions to the van der Waals 
interaction energy, electrostatic energy term, and the desolvation contributions. Of all the 
generated structures, 1000 rotation/translation combinations that have the lowest score are chosen 
for further clustering. Clustering of these 1000 ligand positions is done using pairwise C-α RMSD 
(of ligand residues) as the distance measure, within 10 Å of any receptor atom in these docked 
models. Ligand positions with the most ‘neighbors’ in 9 Å becomes a cluster center, and its 
neighbors the members of the cluster. These are removed from the set and the same procedure 
repeated till all structures are divided into clusters. The biophysical meaning of clustering is 
isolating highly populated low energy basins of the energy landscape, as large clusters are more 
likely to include native structures. This means that the cluster centers representing the largest 
clusters are found to be closest to the native state and are shown to give better results than ranking 
the structures only based on their energies. After clustering with this hierarchical approach, the 
ranked complexes are subjected to a (300 step and fixed backbone) van der Waals minimiza t ion 
using the CHARMM (22) potential to remove potential side chain clashes. ClusPro then outputs 
the centers of the largest clusters. 
 
Calculation of Fe-Fe and Chlorophyll-Heme distances 
The models generated using Cluspro were subjected to a further energy minimization of 
side-chains (fixed backbone) to a 0.01 RMS kcal/mol/Å2 gradient in MOE 2012, using the 
CHARMM27 forcefield (22). In the case of PSI- Fd models, the original PSI structure (1JB0) was 
superimposed on these models to obtain the Fe4S4 center in PsaC. Because the 2CJN structure 
does not include the Fe2S2 center of Fd, these atoms were obtained from the 1ROE Fd NMR 
 181 
structure. To insert the FeS center into 2CJN, residues 37 through 48 of 1ROE were superimposed 
in MOE with the same residues of 1ROE, and the FeS cluster was copied from the 1ROE structure 
into the 2CJN structure.  
Similarly, in the case of PSI- Cytc6 models, the original PSI and Cytc6 (1C6S) structures 
were superimposed on these models to obtain the Chlorophyll molecules in PsaA-PsaB and Heme 
group in Cytc6, respectively. The distances were calculated between the iron atoms in 
corresponding Fe-S centers in PsaC and Fd and between the Heme and Chlorophyll A in PsaA/B 
and Cytc6, respectively. 
 
Results 
PSI-Fd Modeling 
PSI-Fd models generated using Cluspro consisted of a total of 12 separate clusters 
represented by their cluster centers. Table 1 shows these 12 clusters, the number of members 
belonging to each cluster, and the weighted energy scores. Figure 1A shows the RMSD deviation 
between these twelve clusters. These 12 structures are separated by relatively larger RMSD 
distances, with the closest centers (New_7 and New_10) having a RMSD deviation of 3.71 Å. 
These 12 structures can be considered as separate PSI-Fd states that are possibly sampled, 
weighted against the cluster population represented by each cluster center, i.e. cluster 1 center 
represents the structure most sampled and hence closest to the native state of the complex. 
Table 2 shows the number of inter-residue protein contacts and the Fe-Fe distances between 
the FeS centers in PsaC and Fd in each of these 12 cluster centers. The top-3 models show more 
inter-residue contacts compared to previously published models of PSI-Fd (10). The Fe-Fe 
distance is under 13.5 A for most of these models, with the lowest distance shown by 3rd model 
 182 
(8.5 Å). These distances closely compares with the Fe–Fe distances of 8.9–13.1 Å between the 
two FeS centers of PsaC observed in six available crystal structures of PSI from T. elongatus, 
Pisum sativum, and Arabidopsis thaliana (9,23-26), suggesting that the distances between the 
generated models may provide an adequate proximity for rapid electron transfer (27). The Fe-Fe 
distances on average are also smaller than the previously published models. Superposition of these 
12 cluster centers shows Fd sampling multiple rotational modes around the same binding site near 
the PSI FeS center, shown in Figure 1B.  
The agnostic docking protocol in Cluspro generated a total of 18 cluster centers, shown in 
Table 3. Figure 1C shows the superposition of the two top models (cluster centers with largest 
cluster populations) generated by Cluspro using the residues filter and the agnostic docking 
protocol. These two models are very similar with a RMSD of only 1.70 Å. The model shows direct 
interactions between Arg-41, Ser-63, Glu-23 and Glu-93 in Fd and the residues in PsaC, PsaD and 
PsaE that have been shown to be important for binding Fd through mutagenes is studies (Gln-15 in 
PsaC, Lys-34 in PsaC, Lys-104 in PsaD and Arg-39 in PsaE, respectively), given in Table 4. This 
complex structure, the distance between the FeS centers, and two salt bridges between Arg-39 in 
PsaE and Lys-104 in PsaD and Glu-93 and Glu-23 in Fd, is shown in Figure 1D.  
The previously published models of PSI-Fd consisted of a set of 12 models represented by 
only three clusters shown in Figure 2A: cluster I represented by structures 2, 4, 5 and 7; cluster II 
represented by structures 1, 3, 6, 10, 11, 12; cluster III represented by structures 8, 9. These 12 
structures are separated by relatively shorter RMSD distances. Figure 2B shows the comparison 
of RMSD of the newly generated models to the previous models. Structures in cluster I are found 
to be similar to New_12 model; cluster II similar to New_8 model; and cluster III similar to New_6 
model. The previous three clusters (consisting of 12 models) likely represent a subset of the 
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conformational ensemble sampled by PSI-Fd, as seen from the much larger ensemble of structures 
generated by Cluspro, both by residues filter and agnostic approach. 
 
PSI-Cytc6 Modeling 
PSI-Cytc6 models generated using Cluspro consisted of a total of 15 separate clusters 
represented by their cluster centers. Table 5 shows these 15 clusters, the number of members 
belonging to each cluster, and the weighted energy scores. Figure 3A and B show the superposition 
and the RMSD deviation between these 15 cluster centers, respectively. These structures are also 
separated by relatively large RMSD distances, with the closest centers (2 and 9) having a RMSD 
deviation of 8.23 Å. The center of cluster 1 represents the center of the most populated cluster, and 
hence most sampled and closest to the native state of the complex. This structure shows direct 
interactions between the charged residues in Cytc6, PsaF and PsaB, given in Table 6. The complex 
structure, the distance between the Heme and Chlorophyll groups, two salt bridges between Glu-
617 in PsaB and Lys-8 in Cytc6, and between Lys-16 in PsaF and Asp-67 in Cytc6, are shown in 
Figure 3C. The distance between the Heme group and Chlorophyll molecule is 14.03 Å, which is 
high, compared to the value predicted by the Moser-Dutton rule (< 7 Å) for distances suitable for 
electron transfer between these groups (28). 
The agnostic docking protocol in Cluspro generated a total of 29 cluster centers, shown in 
Table 7. The top cluster center shows interactions between the hydrophobic surfaces of Cytc6, 
consisting of residues Val-25 and Met-26, and PsaA and PsaB, consisting of residues Trp-655 and 
Phe-644, shown in Figure 4A and Table 8. The distance between the Heme group and Chlorophyll 
molecule is 9.66 Å, closer to the value predicted by the Moser-Dutton rule. Trp-655 in PsaA and 
Trp-631 in PsaB that are well conserved and have been shown to be important in binding Cytc6 in 
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other species, Spinacia oleracea and Chlamydomonas reinhardtii (29,30), are present at the 
interface between these two interacting proteins, shown in Figure 4B. 
Figure 4C shows the superposition of the top two PSI-Cytc6 models generated by Cluspro 
using the residue filter and the agnostic docking protocol. These models show a RMSD of 16.39 
Å. The first model shows contacts that are rich in electrostatic interactions, whereas as the agnostic 
model shows more hydrophobic contacts. 
 
Discussion 
The rigid body directed-docking calculations yield several observations with regard to 
possible interactions between the electron-transport protein, Fd and Cytc6, and PSI. Docking 
calculations focused on the stromal (PsaC, PsaD, PsaE) and luminal (PsaA, PsaB, PsaF) domains 
of PSI where these electron-transport proteins bind. Previously published PSI-Fd models (10) had 
used a ‘top-down’ approach by using the regions of high Frustration to direct rigid-body docking 
calculations, with distance constraints applied between the possibly interacting residues/regions. 
In this study, only the residues in PSI that have been shown to interact with the electron-transport 
proteins have been used to direct the docking calculations. This allows the receptor and the ligand 
in the rigid-body docking protocol to sample well all the six degrees of freedom, generating ~ 109 
positions of the ligand relative to the receptor. These are then filtered to only keep the structures 
that are thermodynamically most stable, giving preference to the complexes that show interactions 
between the input residues. This provides a ‘bottoms-up’ approach, where the best models are 
predicted from the possible ~ 109 generated models, and hence decreasing the possibility of 
sampling only certain fixed rotational/translational modes of the ligand with respect to the 
receptor. 
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The top cluster center for the PSI-Fd model shows direct interactions between the residues 
experimentally predicted to be important for binding Fd, Gln-15 in PsaC, Lys-34 in PsaC, Lys-
104 in PsaD and Arg-39 in PsaE, and the Arg-41, Ser-63, Glu-23 and Glu-93 residues of Fd. There 
are two salt bridges present between Arg-39 in PsaE and Glu-93 in Fd, and Lys-104 in PsaD and 
Glu-23 in Fd. Low RMSD between the top PSI-Fd models (Figure 1C) generated using the residues 
filter and the agnostic docking protocol highlights the preference for the top binding mode 
generated by using two separate approaches. 
Previous PSI-Fd models can be represented by a subset of the newly generated models; 
hence the new results provide a more comprehensive picture of the possible binding modes. Fd is 
found to sample multiple rotational modes around the same binding site near the PSI FeS center .  
It is possible that Fd may bind in two or more different orientations with PSI. In future, further 
refinement using molecular dynamics simulation on high-performance supercomputers of the 
generated docked complexes, will enable a thorough analysis of the protein dynamics and 
conformational changes that occur upon binding. This will help to determine if the system 
converges to a single binding mode, or if the complex samples multiple modes throughout. 
Two separate models are generated for PSI-Cytc6 using the residues filter and the agnostic 
docking protocol, showing preference for electrostatic and hydrophobic interactions respectively. 
In the first model, Asp-67 in Cytc6, that has been shown experimentally to be important for binding 
with PSI (unpublished data), forms a salt-bridge with Lys-16 in PsaF. In the agnostic model, Trp-
655 in PsaA, that is well conserved and has been shown to be important in binding Cytc6 in other 
species (29,30), forms hydrophobic interactions with Val-25 in Cytc6. Trp-631 in PsaB, also well-
conserved, is also present in close proximity to Cytc6. It is possible that there is an equilibr ium 
between these two modes, with the Cytc6 first interacting with PSI through long-range electrostatic 
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interactions, and then the system equilibrating/relaxing to the second mode where the hydrophobic 
surfaces in PSI and Cytc6 come together by minimizing the area exposed to the solvent. Between 
the two modes, the distance between Heme group and Chlorophyll decreases from 14.03 A to 9.66 
Å, possibly facilitating in the transfer of electrons from Cytc6 to PSI.    
In case of the two PSI-Cytc6 models, future MD simulation in explicit solvent of the two 
binding modes can show if there is an overlap between the models, and if the first model with 
preference for electrostatic interactions finally converges to the model showing preferentia l ly 
hydrophobic interactions in the presence of the surrounding solvent molecules. The distance 
between Heme and Chlorophyll groups can also be expected to decrease further in the presence of 
solvent molecules, as the exposed hydrophobic surfaces will try to minimize the solvent accessible 
area by moving closer. These studies will provide an improved model that describes the atomic 
interactions and the possible binding mechanism at the luminal domain of photosystem I. 
 
Conclusion 
Overall, this study provides a new, detailed insight into visualizing possible binding 
mechanisms between PSI, Fd and Cytc6. These complexes are involved in the electron transfer 
reactions of photosynthesis, and a thorough understanding of their atomic-level interactions and 
dynamics will help in suggesting future mutagenesis experiments for validation purposes. This 
will also enable in the design more efficient mutants of these proteins, to optimize rate of electron 
transfer and hence the rate of energy generation from these systems, leading to the development 
of biologically-based solar energy cells for electricity generation. 
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Table 4.1. PSI-Fd models generated using Cluspro. The 12 clusters, the number of members 
belonging to each cluster, and the weighted energy scores. 
 
 
Cluster Members Representative Weighted Score 
1 247 Center -744 
1 247 Lowest Energy -852 
2 163 Center -712.6 
2 163 Lowest Energy -850.2 
3 140 Center -714.4 
3 140 Lowest Energy -815.2 
4 119 Center -723.2 
4 119 Lowest Energy -882.8 
5 106 Center -712.4 
5 106 Lowest Energy -870.7 
6 53 Center -729.7 
6 53 Lowest Energy -784.2 
7 44 Center -740.2 
7 44 Lowest Energy -808.2 
8 38 Center -723 
8 38 Lowest Energy -769.5 
9 22 Center -747.9 
9 22 Lowest Energy -805.5 
10 18 Center -720.5 
10 18 Lowest Energy -758 
11 13 Center -754.3 
11 13 Lowest Energy -754.3 
12 6 Center -706.3 
12 6 Lowest Energy -753.4 
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Table 4.2. PSI-Fd models contacts and Fe-Fe distances. The number of inter-residue protein 
contacts and the Fe-Fe distances between the FeS centers in PsaC and Fd in each of the 12 cluster 
centers. 
 
 
Models 
Inter-residue 
protein contacts 
Fe-Fe distance 
(Å) 
1 29 11.7 
2 24 9.9 
3 25 8.5 
4 26 9.7 
5 23 13.5 
6 27 9.95 
7 27 12.4 
8 22 10.8 
9 33 15.7 
10 25 12.6 
11 25 21.6 
12 29 12.4 
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Table 4.3. PSI-Fd models generated using Cluspro using agnostic docking. The 18 clusters, 
the number of members belonging to each cluster, and the weighted energy scores. 
 
Cluster Members Representative 
Weighted 
Score 
0 248 Center -615.7 
0 248 Lowest Energy -698.8 
1 99 Center -597.5 
1 99 Lowest Energy -667.4 
2 85 Center -590.8 
2 85 Lowest Energy -685.6 
3 79 Center -592.9 
3 79 Lowest Energy -648.6 
4 77 Center -590.6 
4 77 Lowest Energy -728.1 
5 64 Center -595.3 
5 64 Lowest Energy -711.5 
6 57 Center -607.1 
6 57 Lowest Energy -690.5 
7 51 Center -622 
7 51 Lowest Energy -650.9 
8 43 Center -685.4 
8 43 Lowest Energy -685.4 
9 39 Center -589 
9 39 Lowest Energy -646 
10 32 Center -626.9 
10 32 Lowest Energy -676.7 
11 28 Center -603.9 
11 28 Lowest Energy -636 
12 17 Center -583.1 
12 17 Lowest Energy -632.8 
13 16 Center -585.1 
13 16 Lowest Energy -647.8 
14 14 Center -592.6 
14 14 Lowest Energy -614.9 
15 14 Center -595.4 
15 14 Lowest Energy -684.1 
16 4 Center -585.8 
16 4 Lowest Energy -628.2 
17 4 Center -596.8 
17 4 Lowest Energy -604.7 
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Table 4.4. PSI-Fd best model interactions. Interactions between PSI and Fd in the top model 
(cluster center with largest cluster populations).  
 
Type Chain Position Residue Chain Position Residue 
HB PsaC 13 CYS13.O Fd 41 ARG41.NE 
HB PsaC 15 GLN15.OE1 Fd 41 ARG41.NE 
HB PsaC 18 ARG18.NH1 Fd 23 GLU23.OE1 
HB PsaC 18 ARG18.NE Fd 30 GLU30.OE2 
HB PsaC 18 ARG18.NH2 Fd 31 GLU31.OE1 
HB PsaC 34 LYS34.NZ Fd 63 SER63.OG 
HB PsaD 73 ARG73.NH1 Fd 31 GLU31.OE1 
HB PsaD 76 LYS76.NZ Fd 22 ASP22.OD2 
HB PsaD 104 LYS104.NZ Fd 23 GLU23.OE2 
HB PsaE 3 ARG3.NH1 Fd 66 ASP66.OD1 
HB PsaE 3 ARG3.NH2 Fd 68 ASP68.OD1 
HB PsaE 25 SER25.OG Fd 44 ALA44.O 
HB PsaE 39 ARG39.NH1 Fd 46 SER46.O 
HB PsaE 39 ARG39.NH2 Fd 93 GLU93.OE2 
HB PsaE 48 TYR48.N Fd 35 ASP35.OD2 
HB PsaE 51 SER51.OG Fd 35 ASP35.OD2 
HB PsaE 53 SER53.OG Fd 11 ASP11.OD1 
HB PsaE 57 THR57.O Fd 39 SER39.OG 
HB PsaE 57 THR57.OG1 Fd 47 THR47.OG1 
ION PsaC 18 ARG18.NH1 Fd 23 GLU23.OE1 
ION PsaC 18 ARG18.NH1 Fd 27 ASP27.OD2 
ION PsaC 18 ARG18.NE Fd 30 GLU30.OE2 
ION PsaC 18 ARG18.NH2 Fd 31 GLU31.OE1 
ION PsaD 73 ARG73.NH1 Fd 31 GLU31.OE1 
ION PsaD 76 LYS76.NZ Fd 22 ASP22.OD2 
ION PsaD 104 LYS104.NZ Fd 23 GLU23.OE2 
ION PsaE 3 ARG3.NH1 Fd 66 ASP66.OD1 
ION PsaE 3 ARG3.NH2 Fd 68 ASP68.OD1 
ION PsaE 39 ARG39.NH2 Fd 93 GLU93.OE2 
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Table 4.5. PSI-Cytc6 models generated using Cluspro. The 15 clusters, the number of 
members belonging to each cluster, and the weighted energy scores. 
 
Cluster Members Representative 
Weighted 
Score 
0 234 Center -998.5 
0 234 Lowest Energy -1129.2 
1 149 Center -1036.9 
1 149 Lowest Energy -1132.2 
2 106 Center -942 
2 106 Lowest Energy -1136.3 
3 77 Center -1009.1 
3 77 Lowest Energy -1130.4 
4 70 Center -938.7 
4 70 Lowest Energy -1082 
5 68 Center -980 
5 68 Lowest Energy -1168.5 
6 57 Center -946.3 
6 57 Lowest Energy -1013.4 
7 52 Center -1122.3 
7 52 Lowest Energy -1122.3 
8 46 Center -952.4 
8 46 Lowest Energy -1068.2 
9 36 Center -963.1 
9 36 Lowest Energy -1069.4 
10 26 Center -935.4 
10 26 Lowest Energy -977 
11 25 Center -1015.8 
11 25 Lowest Energy -1058.2 
12 19 Center -927.1 
12 19 Lowest Energy -1017.9 
13 8 Center -934 
13 8 Lowest Energy -1014.3 
14 5 Center -928.4 
14 5 Lowest Energy -977 
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Table 4.6. PSI-Cytc6 best model interactions. Interactions between PSI and Cytc6 in the top 
model. 
 
Type Chain Position Residue Chain Position Residue 
HB PsaA 117 ASP129.OD2 Cytc6 56 ASN56.ND2 
HB PsaA 644 SER659.OG Cytc6 16 ALA16.O 
HB PsaA 645 GLN660.NE2 Cytc6 24 VAL24.O 
HB PsaA 738 SER753.OG Cytc6 25 VAL25.O 
HB PsaB 617 GLU617.OE1 Cytc6 8 LYS8.NZ 
HB PsaB 617 GLU617.OE2 Cytc6 66 THR66.OG1 
HB PsaB 618 SER618.OG Cytc6 13 ASN13.ND2 
HB PsaB 621 TYR621.OH Cytc6 13 ASN13.OD1 
HB PsaB 621 TYR621.OH Cytc6 64 ARG64.NH2 
HB PsaB 628 ASP628.OD1 Cytc6 13 ASN13.N 
HB PsaF 16 LYS16.NZ Cytc6 67 ASP67.O 
HB PsaF 17 ARG17.NH2 Cytc6 64 ARG64.O 
HB PsaF 17 ARG17.NH1 Cytc6 65 LEU65.O 
HYD PsaA 654 LEU669.CD1 Cytc6 25 VAL25.CG1 
ION PsaB 617 GLU617.OE1 Cytc6 8 LYS8.NZ 
ION PsaF 16 LYS16.NZ Cytc6 67 ASP67.OD2 
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Table 4.7. PSI-Cytc6 models generated using Cluspro using agnostic docking. The 29 clusters, 
the number of members belonging to each cluster, and the weighted energy scores. 
 
Cluster Members Representative 
Weighted 
Score 
0 140 Center -663.4 
0 140 Lowest Energy -782.3 
1 118 Center -716 
1 118 Lowest Energy -716 
2 81 Center -618.6 
2 81 Lowest Energy -735.5 
3 65 Center -650.9 
3 65 Lowest Energy -778.3 
4 47 Center -708.1 
4 47 Lowest Energy -725.3 
5 43 Center -689.4 
5 43 Lowest Energy -689.4 
6 42 Center -648.7 
6 42 Lowest Energy -707.7 
7 40 Center -654.3 
7 40 Lowest Energy -721.9 
8 39 Center -724.8 
8 39 Lowest Energy -724.8 
9 38 Center -605.8 
9 38 Lowest Energy -677.8 
10 38 Center -663.4 
10 38 Lowest Energy -670.8 
11 37 Center -620 
11 37 Lowest Energy -721 
12 37 Center -673.5 
12 37 Lowest Energy -687.9 
13 30 Center -624.9 
13 30 Lowest Energy -665.6 
14 27 Center -618.4 
14 27 Lowest Energy -709.6 
15 24 Center -617.4 
15 24 Lowest Energy -654.2 
16 18 Center -662.2 
16 18 Lowest Energy -662.2 
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Table 4.7 continued 
 
Cluster Members Representative 
Weighted 
Score 
17 14 Center -644.7 
17 14 Lowest Energy -644.7 
18 13 Center -610.6 
18 13 Lowest Energy -635.6 
19 13 Center -694.2 
19 13 Lowest Energy -694.2 
20 13 Center -691.9 
20 13 Lowest Energy -691.9 
21 12 Center -636.4 
21 12 Lowest Energy -636.4 
22 11 Center -613.6 
22 11 Lowest Energy -662.3 
23 11 Center -677.8 
23 11 Lowest Energy -677.8 
24 11 Center -641.5 
24 11 Lowest Energy -641.5 
25 11 Center -614.8 
25 11 Lowest Energy -646.2 
26 6 Center -607.2 
26 6 Lowest Energy -652.1 
27 2 Center -608.1 
27 2 Lowest Energy -609.1 
28 1 Center -613.8 
28 1 Lowest Energy -613.8 
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Table 4.8. PSI-Cytc6 best model interactions (agnostic docking). Interactions between PSI 
and Cytc6 in the top model. 
 
Type Chain Position Residue Chain Position Residue 
HB PsaA 609 THR624.OG1 Cytc6 49 TYR49.OH 
HB PsaA 617 SER632.OG Cytc6 55 LYS55.NZ 
HB PsaA 618 HIS633.O Cytc6 49 TYR49.OH 
HB PsaA 623 ASN638.ND2 Cytc6 56 ASN56.O 
HB PsaA 644 SER659.OG Cytc6 60 ALA60.O 
HB PsaA 644 SER659.OG Cytc6 64 ARG64.NE 
HB PsaA 645 GLN660.NE2 Cytc6 60 ALA60.O 
HB PsaA 645 GLN660.NE2 Cytc6 61 PHE61.O 
HB PsaA 735 ARG750.NH2 Cytc6 53 HIS53.O 
HB PsaA 738 SER753.OG Cytc6 63 GLY63.N 
HB PsaB 636 GLN636.NE2 Cytc6 16 ALA16.O 
HYD PsaA 640 TRP655.CZ3 Cytc6 25 VAL25.CG1 
HYD PsaB 644 PHE644.CE1 Cytc6 26 MET26.CE 
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Figures 4.1. PSI-Fd models generated using Cluspro. (A) RMSD deviation between 12 cluster 
center. (B) Superposition of 12 cluster centers. (C) Superposition of two top models (cluster 
centers with largest cluster populations) generated by Cluspro using residues filter, Fd in green, 
and agnostic docking protocol, Fd in blue. (D) Distance between FeS centers and salt bridges 
between PSI and Fd in top model. 
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Figures 4.2. Comparison with previously published PSI-Fd models. (A) RMSD deviation 
between previously published models of PSI-Fd consisting of 12 models represented by 3 clusters. 
(B) Comparison of RMSD of the newly generated models to the previous models. 
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Figures 4.3. PSI-Cytc6 models generated using Cluspro. (A) Superposition of 15 cluster 
centers. (B) RMSD deviation between 15 cluster center. (C) Distance between Heme and 
Chlorophyll groups and salt bridges between PSI and Cytc6 in top model. PsaA in purple, PsaB in 
orange, PsaF in cyan and Cytc6 in red. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 206 
 
 
 
 
Figures 4.3 continued 
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Figures 4.3 continued 
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Figures 4.4. PSI-Cytc6 models generated using Cluspro using agnostic docking. (A) Distance 
between Heme and Chlorophyll groups and salt bridges between PSI and Cytc6 in top model. PsaA 
in purple, PsaB in orange, PsaF in cyan and Cytc6 in red. (B) Trp-655 and Trp-631 present at the 
interface between Heme (pink) and Chlorophyll (green). (C) Superposition of the top two PSI-
Cytc6 models generated by Cluspro using the residue filter (red) and the agnostic docking protocol 
(green). 
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CONCLUSION 
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The biological levels of organization in living beings form a highly structured hierarchy. 
This range from a single atom, all the way up to the biosphere. The different subunits- atoms, 
molecules, amino acid sequences, proteins, cells, tissues, organs, etc., together (as a system) 
perform the functions necessary for survival and reproduction. Thus, to understand the function at 
the macroscopic scale that we see around us, it is important to understand the function at the 
microscopic level first.  
There is a direct relationship between the structure of the proteins and the diverse functions 
that they can perform. The flexible nature and dynamics of macromolecules forms an 
indispensable link between their structure and function. The interactions that drive most of the 
biological processes are also influenced by this dynamic nature of biological molecules. The study 
presented here explores this structure-dynamics-function relationship. Important insights were 
gained about the dynamics of interactions in proteins, between protein: ligands and protein: protein 
systems. Throughout this work, different molecular modeling and simulation technologies were 
employed to tackle specific problems in the field of molecular and structural biophysics. 
 In CHAPTER 1, an emerging non-covalent interaction is identified to potentially play 
important roles in protein systems in: i) maintaining stability of the folded structure of protein 
monomers, ii) dimeric interface interactions i.e., forming quaternary assemblies, and iii) active-
site interactions in maintaining function. Experimental work like mutagenesis studies can help to 
validate these results in terms of physical effects of these interactions on the stability of the protein. 
These interactions have been exploited in field of drug-discovery in developing active-site 
inhibitors. Hence, in future it is imperative to include these interactions in the description of new 
forcefields and docking scoring-functions in order to make better predictions both in the fields of 
molecular modelling and structure-based drug discovery.  
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CHAPTER 2 focuses on understanding the tissue specific functions of GPRC6A and the 
structural basis for its binding to distinct ligands, elucidating new systems biology involving 
coordinated metabolic processes. Future molecular dynamics simulations of the T:GPRC6A 
models, will likely be able to identify the most stable binding modes of ligands in GPRC6A and 
allow a detailed structure-based description of binding poses.  The study also takes the first step 
for the development of agonists for GPRC6A that may stimulate insulin production, -cell 
proliferation and peripheral tissue sensitivity, and thereby provide a new treatment for Type II 
diabetes.  Conversely, antagonists to GPRC6A might represent new treatments to retard the 
progression of prostate cancer.  . 
CHAPTER 3 exemplifies a successful MD simulation and high-throughput virtua l 
screening approach to drug discovery, targeting a protein-protein complex, and shows the 
importance of explicitly including the flexibility of proteins in making better predictions in drug-
discovery. New protein targets for diseases like cancer and diabetes are being discovered rapidly. 
The same approach can be extended to target these proteins, using even larger compound databases 
covering millions of compounds. This can increase dramatically the number and diversity of 
compounds that can be identified, while at the same time providing a more realistic approach that 
accounts for the dynamic nature of macromolecules and their complexes under physiologica l 
conditions.  
The work in CHAPTER 4 allows the atomic-level description of protein-protein 
interactions and dynamics between electron transport proteins in PS1. Information obtained from 
the docking models and ongoing MD simulations can be used to guide future experimental studies, 
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enabling the design of high affinity variants of these proteins to optimize electron transfer and 
leading to the development of biologically-based solar energy cells for electricity generation. 
Overall, the work presented here explores the importance of dynamics in describing both 
the structure and the function of macromolecules. It becomes indispensable to spend more time 
and resources in the study of this field, as it forms an important link between the thousands of 
protein structures solved till now, and their functions. An unwanted change in the 
structure/interactions/dynamics can lead to a change in the function, leading to diseases. At the 
same time, this dynamic nature of biological molecules can be exploited for making better drugs 
and improving the efficiency of renewable sources of energy. 
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